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ABSTRACT

A Multilevel Analysis to Understand the Role of the Federal Vaccine Financing Program in
Socioeconomic Disparities in Vaccination Coverage among Children and Adolescents
in New York City

by
Alexandra Ternier

Advisor: Heidi Jones, PhD

Objectives: The purpose of this study was to examine the role of the federal vaccine financing
program, the Vaccines For Children (VFC) program, in vaccine series completeness among
children and adolescents in New York City. In addition, we aimed to investigate possible effect
measure modification by selected neighborhood variables to explain socioeconomic disparities in
vaccination coverage.

Methods: We used data from the New York City (NYC) Citywide Immunization Registry (CIR)
and the American Community Survey (ACS) to examine vaccine series completeness among
children 19-35 months and adolescents 13-17 years of age, with VFC status as the main exposure
controlling for selected individual- and neighborhood-level factors. Neighborhood poverty and
VFC-facility concentration were explored as confounders and effect measure modifiers in the
relationship between VFC status and vaccine series completeness. Data were analyzed using
Poisson and multilevel log-binomial models. A separate spatial analysis was conducted using
iii

spatial scan statistics to identify clusters of undervaccination and ArcGIS to examine
intersections between neighborhood vaccination coverage and neighborhood poverty.

Results: The effect of VFC status was minimal among children (prevalence ratio, PR=1.06,
p<.0001). In contrast, the effect among adolescents was markedly higher than in the younger
group (PR=1.72, p<.0001). Overall coverage in this group was suboptimal. When stratified by
vaccine series, HPV was found to be a significant factor in the low overall coverage among
adolescents. Disparities were also found within racial and ethnic sub-groups where Hispanic and
Asian adolescents had superior coverage compared to non-Hispanic adolescents and those from
other racial groups. In the spatial analysis, we identified geographic variations in coverage
citywide and specific neighborhoods with low vaccination coverage.

Conclusion: Efforts to reduce vaccination coverage disparities based on VFC status should target
primarily adolescents. Improving overall adolescent coverage must consider the barriers to HPV
vaccination. For both children and adolescents, identifying the root causes of neighborhood
coverage variations can help reduce disparities overall.
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Chapter One: Introduction

1.1 Background and Significance
1.1.1 The financial burden of vaccines
Each year, the Advisory Committee on Immunization Practices (ACIP), the federal body
responsible for making decisions on vaccine use in the United States (US), releases a set of
vaccine recommendations affecting millions of American children and adults. The committee, in
consultation with such organizations as the American Academy of Pediatrics and the American
Academy of Family Physicians, votes to add, expand, or change vaccine recommendations, and
also makes decisions on which vaccines should be covered by the federal vaccine financing
program or Vaccines for Children (VFC) program. Providing access to the expanding set of
vaccines recommended for children and adolescents each year has become increasingly
expensive for the federal government and private insurers. Today the cost to complete the current
ACIP vaccine schedule for a child up to age 18 is approximately $2,250, compared to $195 in
19951. Vaccines added since 2000 are the most expensive. For example, the 3-dose human
papillomavirus (HPV) vaccine costs approximately $480, compared to $56 for the two-dose
measles, mumps, rubella (MMR) series1. In the US, about half of children are eligible to receive
vaccines through the public VFC program2.

Among children who are privately-insured and

underinsured however, there are financial barriers that impede access to vaccination. These
barriers include cost-sharing (co-pays and deductibles) imposed by insurance plans for
vaccination visits, and the requirement in some states and jurisdictions, that underinsured
children whose parents cannot afford their share of the cost of vaccination may only receive free
vaccines at specific approved sites. Numerous reports on vaccine funding show that publicly5

insured children have higher vaccination coverage rates and more timely vaccinations than
children who are privately insured3-9. The coverage disparity may be attributed to the vaccine
funding barriers and other factors found at the individual and neighborhood levels.

1.1.2 Barriers to vaccination among the privately-insured children
Children who are uninsured, underinsured, eligible for Medicaid, and American Indian or
Alaskan natives are eligible for the VFC program. In New York City and a few other
jurisdictions, children enrolled in the Children’s Health Insurance Program (CHIP) also qualify
to receive VFC vaccines.

The majority of children who are not eligible for the VFC program

are privately-insured and have vaccine coverage through their respective plans. Nationally, a
subset of children, however, remains underserved despite the far-reaching coverage achieved by
the current system.

First, some children are underinsured when private plans do not include coverage for any
vaccines, or specific vaccines, or cap vaccine reimbursement at a set dollar amount or number of
visits. Nationally, an estimated 11% of young children 19-35 months old and 20% of adolescents
aged 13-17 years (NIS and NIS-Teen survey population) belong to this category1. The federal
government allocates part of its funding to be applied toward underinsured children and
adolescents with the stipulation that vaccines can only be administered to the underinsured in
Federally Qualified Health Centers (FQHCs), Rural Health Clinics (RHCs), or other approved
designees. This stipulation differs from the requirements for low-income, VFC-covered children
who can receive vaccines in any setting, private or public, as long as the provider participates in
VFC. In many jurisdictions throughout the US, when coverage is not adequate for a vaccine,
6

children who are underinsured are referred by their primary care providers to FQHCs or RHCs
for vaccination, away from the medical home. The referral can be a barrier to timely vaccination,
especially since privately insured parents do not typically seek care in public settings10,11. In
addition, FQHCs and RHCs do not exist in many communities since they are mandated to
provide care in geographically underserved areas, which further limits access to these centers by
privately-insured children7. Underinsured children who are unable to access FQHCs or RHCs
may receive vaccination in public health department clinics. However, with the high number of
vaccines and increasing vaccine costs, funding allocated to cover local health department
vaccination activities (called 317 grant funding), has not been adequate in recent years8. In New
York City, underinsured children can receive VFC vaccines in any setting as long as the facility
participates in the VFC program. There is no need for a referral and as a result, they are
vaccinated in the medical home.

Second, among privately-insured children whose plans cover all vaccines, the financial impact of
adding new vaccines or vaccine doses to the schedule represents a barrier to many parents 8,12. In
2011, up to 20% of privately-insured children had coverage that did not adequately cover the
costs of vaccination2. Because of the high cost of the new vaccines and the uncertainty of
reimbursement when a vaccine is new, many providers resort to delaying offering the vaccine or
charging parents upfront for the vaccines1. In 2011, a national survey among 190 private
pediatricians and 181 family physicians found that 60% of physicians reported that at least some
parents in their practice had deferred or refused a vaccine because of out-of-pocket costs or
uncertain insurance coverage especially for new vaccines1.

Further, in the same survey, the

physicians reported using different strategies to address vaccine cost issues with parents. These
7

strategies include informing parents that they will be billed if their plan does not cover a vaccine,
and delaying vaccination until coverage is in place1. In addition to uncertainty of coverage, there
is the burden for parents to meet the necessary deductibles and co-payments required for each
vaccination visit. Even with the availability of combination vaccines, parents must make frequent
vaccination visits due to the high number of vaccines currently recommended, which adds to the
financial burden. For some parents, this factor may delay a trip to the pediatrician or force
parents to forgo a vaccination visit altogether13.

1.1.3 Gaps in vaccine series completeness between publicly-insured and privately-insured
children and adolescents: a form of reverse disparity.
In a 2009 report on the challenges of the current vaccine financing system, researchers estimate
that the barriers that are specific to underinsurance were associated with childhood vaccination
rates 10 to 15 percent lower, compared to rates among children with no gaps in coverage13. In
June 2013, a geographic analysis of HPV vaccination coverage in New York City showed that
adolescents living in high VFC-enrollment areas were more likely to initiate and complete the
series than adolescents living in low enrollment areas9. Overall, the study estimated that on
average 74% of adolescent females in high enrollment areas had initiated the HPV series,
compared to 45% of females in low enrollment areas9. The differences that characterize
vaccination coverage rates between publicly-insured and privately-insured children and
adolescents can be viewed as a form of disparity, albeit a reverse disparity, that is based on
socioeconomic status. The success of the VFC program is not directly responsible for the
coverage disparity, however it highlights an important public health issue that warrants more
comprehensive research than currently available in the literature.
8

1.1.4 Non-economic predictors of vaccination
Individual-level predictors
Understanding the factors associated with suboptimal compliance with vaccination requirements
is key to preventing 14 million cases of vaccine-preventable disease occurring in the US each
year14. Factors that affect vaccine series completeness among children reside primarily at the
parental or guardian level since most vaccines are recommended before a child reaches age 6.
Despite the roles of pediatricians, public health agencies and schools in encouraging or enforcing
vaccination requirements, children’s primary caretakers have a great deal of influence on
whether they receive timely immunizations or get vaccinated at all. Parental characteristics that
are associated with vaccine series completeness among children are well documented in the
literature. For most vaccine series, maternal age, education, poverty status, race, ethnicity, and
foreign-birth status have been cited among the predictors9,15,16,17.

Family characteristics also play a significant role in whether children get vaccinated. In the
literature, such characteristics as family composition, size, and dysfunction level have been
linked with compliance with and timely receipt of vaccines18,19. Lower family dysfunction, the
presence of a 2-parent household compared to a single parent, and increased family size are
associated with increased odds of vaccine series completeness18,19. Caring for multiple children
may offer opportunities for vaccination. For example, pediatricians providing care for siblings
may take the opportunity to offer or remind parents of needed vaccinations for all siblings. Also,
mothers may not know when vaccination is due, the importance of vaccination or where to go for
care; they may also find it difficult to bring children to the frequent vaccination visits that are
9

required amidst the demands of their daily lives. The presence of a second parent in the
household may provide this type of support.

Furthermore, parental beliefs and attitudes regarding vaccination have been linked to vaccine
series completeness. These beliefs may be rooted in parents’ personal experiences and the
environments in which they live. Results from a 2005 systematic review of 15 qualitative studies
identified some of the most common barriers to childhood vaccination which include fear for
adverse effects, concerns that vaccinations are painful, and lack of awareness of the vaccination
schedule 20. In a more recent review of 31 studies, researchers found that vaccine-accepting
parents believe that vaccines are safe and effective, and trusted the advice of health care
professionals21. These factors have been studied predominantly with data on preschool children.
Among school-aged children however, other factors take prominence in parental vaccination
decisions, in addition to those held regarding younger children. Often parents of school-aged
children who resist vaccination report that their children are not at risk or that the disease is not
severe enough to warrant the inconvenience of vaccination22. Among adolescents, the dynamics
of decision-making, acceptance, and actual receipt of vaccination appear to differ from those that
take place in the younger age groups. First, adolescents have fewer preventive care visits during
which needed vaccination can be administered 23. Second, parents and providers have to contend
with minor consent issues, since depending on the age at vaccination, adolescents are involved in
the decision. Third, parents may also have strongly held assumptions about specific vaccines
which may hinder compliance. In the case of HPV, the association between parental beliefs and
vaccine acceptability has been studied extensively. Ranking high among the reasons parents
choose not to vaccinate are issues of HPV vaccine safety and effectiveness, the belief that their
10

adolescent children have a low susceptibility to disease, and the perception that receipt of the
vaccine will encourage sexual activity24.

We also found evidence in the literature that social environments exert some influence on
parental beliefs and attitudes. Having family and friends with positive views of vaccine was
strongly associated with vaccination compliance25. The effects of specific networks (people
networks i.e. providers, family members, etc. and source networks i.e. internet, journals, etc.) on
vaccination choices have been studied26. Interestingly, one study found that people networks had
a larger impact on parents’ vaccine decisions than the parents’ own characteristics including age,
education, gender, race, and income .26

Provider and community-level predictors
The individual-level characteristics described above may influence children’s vaccine
completeness with their direct and/or indirect effects. They may also interact with communitylevel factors to influence the likelihood of vaccination. The community-level factors most
frequently cited in these associations are neighborhood SES, neighborhood racial and ethnic
composition (homogeneity level), density and type of medical facility available in the proximate
environment, and local vaccination policy27-30. In 2012, Gaudino and Robison investigated
interactions between community influences and individual markers on parents claiming personal
belief exemptions to school immunization requirements. In that study, the authors demonstrated
statistically significant effect modification between core individual risk factors and community
characteristics, and showed that the relationship between parental attitude towards vaccination
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and likelihood of vaccination was modified by whether area of residence provided the
convenience of vaccination exemption30.

1.2. Contribution to the current literature
The effect of insurance status on vaccination depends primarily on the vaccine financing system
in the state of residence. For those who have private insurance, the prevailing financing system
may dictate the likelihood of vaccination and whether parents opt for certain vaccines or whether
providers stock and recommend certain vaccines. In 2004, Santoli and colleagues conducted a
study on insurance status and vaccination coverage among US preschool children and concluded
that the vaccination disparity among publicly, privately, and uninsured children was dramatic31.
Much has changed since that study with the adoption of the Affordable Care Act (ACA) vaccine
coverage requirements for insurance plans by some states, including New York State. However,
many subpopulations of children remain at a disadvantage due to the type of insurance they hold.
Recent research findings substantiate significant differences in vaccination coverage between
publicly- and privately-insured children, however the direction of this association has been
mixed. Several studies have found that children who are privately-insured are more likely to be
up-to-date (UTD) with their vaccine schedules than those with public insurance32-36, while others
have reported the opposite: publicly-insured children are better off when it comes to receiving
recommended vaccines37,38. Only a few studies to date have investigated individual- or
community-level factors with VFC status simultaneously. The current research considers VFC
eligibility and its relationship with other significant predictors. It allows for adjusting in a
multilevel context to address an important gap in the literature and provide critical insights on
why coverage differences persist.
12

This study contributes to the current literature in several ways. First, as mentioned above, very
few multilevel studies currently exist with vaccination status as the outcome of interest. In the
recent literature, such studies have focused primarily on cross-national comparisons of vaccine
uptake or adolescent HPV coverage. This study includes variables at multiple levels of influence,
and explores cross-level effect measure modification among predictors. Second, most previous
studies on vaccination completeness have used state or national-level NIS data (NIS-Child and
NIS-Teen). The limitations of the NIS methodology are well known; they include a small area
sample size (adjusted by weighting) and issues associated with using telephone surveys and selfreports39,40. In addition, the NIS surveys do not include neighborhood-level data, which in light
of the significance of these data, could strengthen the conclusions of the surveys. A number of
other studies that have not used NIS data have been constrained by limited data or scope, often in
their use of single data systems such as Electronic Health Record systems (EHR). As a result,
many lack generalizability for their focus on a specific setting or population, or methods that
preclude the collection of important variables. Immunization registries offer many unique
advantages for the study of vaccination coverage disparity in that they consolidate records from
multiple providers and systems, receive data from primary sources often in real time, have high
standards of data quality (accuracy and completeness), and include a wealth of information rarely
found in one data system. Additionally, immunization registries track demographic (address and
insurance status) and vaccination histories over time which allows retrospective analyses. The
current study uses large datasets drawn from the New York Citywide Immunization Registry
(CIR), a population-based registry that captures both birth records and provider records. The CIR
was implemented in 1996 and is one of the most mature immunization registries in the nation.
With over 90% participation and completeness among individuals less than 19 years of age and
13

90% of NYC providers reporting to the registry on a regular basis (2015 CDC Annual Report),
the CIR reflects population capture and population characteristics in a way that is essential to
understanding the variations in vaccination coverage that the current study seeks to examine.
These features also make CIR data highly representative of the NYC population, therefore
suitable for informing the NYC Department of Health in its efforts and for generating broader
scientific knowledge.

1.3. Study objectives, aims, and hypotheses
The analysis focuses on two cohorts and vaccine series: children 19-35 months old for the
childhood vaccine series and adolescents 13 to 17 years of age for the adolescent vaccine series.
The overall objective of this study was to use two separate age groups to examine the impact of
VFC status on vaccine series completeness in each group, controlling for a number of individualand neighborhood-level factors. Further, we determine whether the effect of VFC status is
consistent among the groups. We do not seek to explain differences, as the current study is
descriptive.

The first aim of the study was to estimate the independent effect of VFC status on vaccination
completeness among children 19-35 months and adolescents 13-17 years of age in New York
City using log-binomial regression and controlling for individual-level factors. For this aim, we
tested the hypothesis that children and adolescents who are eligible for VFC are more likely to be
up-to-date with recommended immunizations than children who are privately-insured,
controlling for age, gender, race, ethnicity, mother’s age and nativity status as described in
Chapter 2. The second aim of the study was to use multilevel models to assess effect measure
14

modification by neighborhood VFC-facility concentration and neighborhood SES on the
relationship between VFC status and vaccination completeness, controlling for individual-level
covariates. The principal hypotheses for this aim were that concentration of VFC- participating
facilities within neighborhoods increases the effect of individual VFC status on vaccination
completion among NYC children and adolescents and that VFC-enrolled children and
adolescents living in low SES areas have higher rates of vaccination completion than those living
in high SES area as described in Chapter 3. Lastly for the third aim, we conducted a geographic
analysis using SaTScan to test whether clustering patterns of vaccine series completeness existed
in NYC, and ArcGIS to determine if identified patterns coincided with neighborhood VFC
enrollment and VFC-facility concentration as described in Chapter 4.

1.4 Conceptual framework
A model adapted from the Health Belief Model (HBM) and Anderson’s Behavioral Model of
Health Services Use provides the theoretical foundation for this research. The Health Belief
Model is a psychosocial framework developed during the 1950-1960 period by Public Health
Service investigators seeking to explain the reasons why parents failed to vaccinate their
children41. At its core is the concept that personal beliefs influence health behavior. The model is
based on the premises that in order for individuals to take action to prevent disease, they must
believe that they are personally susceptible, that the occurrence of disease would have moderate
severity on some aspects of their lives, that taking preventive action will be beneficial in
preventing disease, and finally, that personal barriers to behavior change are surmountable42.
Thus, the model relies on four main constructs: perceived susceptibility, seriousness, benefits
and barriers. Self-efficacy, which refers to one’s ability to take action43, was later added to the
15

four constructs of the HBM (figure 1.1). Since its first application in the 1950’s, the HBM has
been used extensively in the area of vaccine-preventable disease to explain the factors that
influence parental decision to vaccinate.

The Behavioral Model (BM) of Health Services Use developed by Anderson has been used
extensively in research investigating the use of health services44. The model uses a multilevel
approach that incorporates both individual and contextual determinants of health services use44.
This model has gone through a few iterations but the version selected for this analysis is the 1995
model45 (figure 1.2). Anderson’s model considers multiple levels of influence, i.e. predisposing,
enabling, and needs factors at both the individual and contextual levels. The choice of this model
is based on its focus on contextual barriers to health-seeking behavior. As hypothesized in the
study, neighborhood characteristics may play an important, enabling role in children’s actual
receipt of immunizations. For example, a neighborhood with few VFC-enrolled providers may
have fewer up-to-date VFC eligible children than one with a high concentration of VFC-enrolled
providers.

The adapted model used as a framework for this study is presented in figure 1.3. The rationale
for creating and using the HBM/BM-adapted model is that it provides a framework for
understanding variability in vaccination seeking behavior at the individual level as well as
accounting for the variability beyond individual choice. Specifically, the proposed model allows
us to better explain patterns of vaccination coverage among publicly- and privately-insured
children since it addresses the multilevel factors that can potentially play a role in the actual
receipt of vaccines. Furthermore, the adapted model allows us to consider more explicitly the
16

contribution of intra-personal factors (i.e. perceived benefits, susceptibility, and vaccine safety)
and provides a backdrop for understanding how decisions regarding vaccination are made.
Despite the roles of pediatricians, public health agencies and schools in encouraging or enforcing
vaccination requirements, these intra-personal factors have a great deal of influence on whether
children receive timely immunizations or get vaccinated at all. The health belief model, which
proposes that health behavior is determined by personal beliefs, has been used to explain parents’
behavior regarding vaccination41. It holds that individual perceptions about disease susceptibility
and severity, vaccine efficacy, and access all shape parents’ behavior41. These factors have
distinct relationships with the variables of the study. For example, child’s age and gender may
influence a mother’s perceived seriousness or susceptibility for vaccine-preventable disease,
which in turn influences the likelihood of vaccination. Similarly, mother’s age or nativity status
may affect self-efficacy, e.g. being young or non-US native may be an impediment to one’s
ability to secure needed services. The interplay of these individual-level factors can be very
powerful in the decision to vaccinate or not to vaccinate. The problem is however, individual
factors only explain about 30 to 40% of the variation in vaccination behavior41. Consequently,
the HBM model is not suited to address other spheres of influence such as neighborhood, social
networks, and family characteristics. As a complement to the HBM model, the BM model with
its focus on contextual factors, provides a way to consider enabling resources, especially those
related to access to vaccination. For example in the proposed study, we hypothesize that
concentration of VFC-enrolled providers within neighborhoods and neighborhood SES will play
a role in the relationship between children’s VFC status and vaccine series completion. Such
interactions can only be demonstrated with explicit characterizations of individual and contextual
factors. This is made possible by the adapted model.
17

1.5 Conclusion
The VFC program removes economic barriers to vaccination for children whose parents cannot
afford such services. At the same time, the system makes evident vulnerabilities in those who do
not participate in the program. Evidence-based research exists that focuses on the extent and
impact of the economic barriers to vaccination among the privately-insured. However, the
evidence for the impact of the VFC program on immunization status is mixed. Existing literature
on vaccination completion is focused primarily on individual-level factors, while community
factors remain largely unexplored. Health behavior, including preventive behavior, however,
tends to have multiple levels of influences46, and influences may also interact across levels. The
goal of this study was to provide an empirical basis for understanding the relationship between
VFC status and selected demographic and neighborhood factors in predicting vaccine series
completeness in NYC. In the following chapters, we examine independent effects of VFC status
on vaccine series completeness and assess whether neighborhood factors modify the relationship.
Additionally, we identify and describe clusters of undervaccination in NYC and show whether
the clusters overlap with neighborhood poverty. Findings from this analysis can inform our
understanding of population risk, and influence policy decisions aimed at reducing vaccination
coverage disparities among the city’s children and adolescents.

18

FIGURES

Figure 1.1 The Health Belief Model (HBM)

Figure 1.2 The Behavior Model (BM) of Health Care Utilization
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Figure 1.3 Model of vaccine series completeness adapted from the Health Belief Model (Rosenstock 1994) and
the Behavioral Model of Health Services Use (Anderson 1995)

. Figure illustrates the framework guiding this reseach. Only variables in red areas are included in the analysis.
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Chapter Two: Independent effects of VFC status on vaccine series completeness among
children and adolescents in New York City

2.1 Introduction
In the United States (US), the current vaccine financing system follows a mixed model of public
and private coverage. The federal government purchases approximately 53% of all pediatric
vaccine doses directly from manufacturers and the remaining 47% are purchased by privatesector physicians47. The stock from which children receive vaccines depends on the type of
insurance they hold. On the one hand, publicly-purchased vaccines are allocated to providers
enrolled in the federal Vaccines For Children (VFC) program for VFC-eligible children and to
federally-qualified, rural, or local health department clinics to vaccinate underinsured children.
On the other hand, private vaccine stocks are used to vaccinate privately-insured children, and
private insurance plans cover the costs of the vaccine product and administration, in part or in
full depending on the plan and whether the jurisdiction mandates the coverage of required
vaccination. In New York City, VFC vaccines are allocated to public and private health care
facilities to cover vaccine costs for eligible children under age 19 who fall in the following
categories: uninsured, underinsured, Native-American or Alaskan Native, enrolled in Medicaid,
or participating in the Child Health Insurance Program (CHIP). Children enrolled in the CHIP
are those whose families earn an income that exceeds the Medicaid financial level but cannot
afford private insurance. Underinsured children who qualify for VFC vaccines are those whose
private insurance does not cover vaccines or covers only selected vaccines, or those who have
reached the vaccine coverage cap set by the plan. In many jurisdictions throughout the US,
children with private plans that cover only part of the vaccine cost or those who have high,
unmet deductibles are not eligible to receive VFC vaccines. According to the US Centers for
21

Disease Control and Prevention (CDC), only an estimated 1.5% of NYC children under age 19
fall into this category each year, thanks in part to a New York State law requiring insurance plans
to cover all vaccines recommended by the Advisory Committee on Immunization practices
(ACIP)48. The VFC vaccine management office in New York City distributes approximately 3.3
million vaccine doses yearly to over 1,400 providers registered with the program48. Nationally,
about 57% of children under the age of 19 are eligible to receive ACIP-recommended vaccines
through the VFC program3. In New York City, an estimated 65% of children under the age of 19
meet the eligibility criteria to receive VFC vaccines48. An additional 7% representing children
enrolled in the CHIP program also receive VFC vaccines.

With the widespread coverage made possible by the VFC program, many children and
adolescents have access to ACIP-recommended vaccines and as a result substantial gains have
been achieved in the areas of vaccination coverage, and vaccine-preventable morbidity and
mortality nationwide. The improvements achieved during the VFC era were the focus of a 2013
report by the CDC that used immunization survey data from the US Immunization Survey (USIS)
for 1967-1985, the National Health Interview Survey (NHIS) for 1991–1993, and the National
Immunization Survey (NIS) for 1994–2012. The report indicates that since the implementation
of the VFC program in 1994, coverage rates for all routinely-recommended vaccines for children
and adolescents have gradually increased and most are currently at or near 90 percent 50. As a
result, 322 million illnesses, 21 million hospitalizations, and 732,000 deaths (over lifetime) have
been prevented among the 78.6 million children born during the 1994-2013 period following the
implementation of the VFC program51.
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The overarching goal of the VFC program is to eliminate cost as a barrier to vaccination, and as
it relates to low-income, uninsured children, the VFC program has met its objectives. According
to a 2009 review, the program has been very successful in providing access to free vaccination to
children aged zero through 18 years who are publicly insured or uninsured 52. A key achievement
in the implementation of the VFC program has been the increase in the number of children
vaccinated in the medical home by their regular primary care physicians, thereby reducing
vaccination referrals53. Nationwide, over 44,000 providers are enrolled in the VFC program, of
which approximately 73% are private providers.4 In New York City, about 85% of pediatric
provider sites participate in the program48.

The VFC program removes barriers to vaccination for children whose parents cannot afford such
services. However, at the same time, the system highlights vulnerabilities in those who do not
participate in the program. The current public/private vaccine financing structure does provide
coverage for the majority of children and adolescents, those who are eligible for the public VFC
program and privately-insured children whose insurance plan covers all costs associated with
vaccination. Unfortunately, however, there are segments of the children population for whom
financial barriers remain. Nationally, nearly 11% of children are underinsured, and studies
estimate that they are also disproportionately under-covered for age-appropriate immunizations,
with a gap of 10 to 15% less coverage when compared to VFC-covered children54. Some studies
also show that VFC-covered children have higher immunization rates than privately-insured
children in general. At the state level, findings indicate that underinsurance is responsible for
more missed opportunities, when states with and without coverage for underinsured children are
compared55. A missed opportunity, as defined by the CDC, occurs during a visit at which
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immunizations were due but not given and no contraindications were present55. Clearly, timely
completion of recommended vaccines among children and adolescents is not determined by
insurance coverage alone. Socioeconomic and demographic factors have been found to predict
many health outcomes56. However, the verdict is somewhat mixed in the literature on vaccine
series completeness. In an in-hospital, 9-month survey among 204 mothers of newborn infants to
identify the characteristics of mothers who comply with the recommended birth Hepatitis B
vaccine, researchers found that mothers whose infants were vaccinated were less educated and
had lower socioeconomic status (SES) than those who chose not to vaccinate57. In another study,
researchers using data from the 2003 NIS found that vaccination compliance among children 19
to 35 months of age was associated with low maternal educational levels and socioeconomic
status58. In contrast to these two reports, a study of a randomly selected cohort of 2,519 children
less than 36 months of age using stratified cluster sampling based on socioeconomic status
concluded that high SES children had higher rates of coverage59. By age 24 months, children in
the upper SES stratum of the study were better immunized than those in the medium and low
strata, with statistically significant differences between high and low SES (64.0% vs. 42.3%,
p<.005)59. Children in the medium SES stratum were better immunized than low SES children
also at a statistically significant level59. One of the possible reasons for the inconsistent findings
about the role of socioeconomic status may be the VFC program, which provides free vaccines to
children of low SES and removes potential financial barriers to vaccination. In other reports,
race/ethnicity, parental and facility characteristics were also associated with vaccine series
completeness.56,58
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The goal of this paper was to elucidate the role of the VFC program in vaccine series
completeness among children 19 to 35 months and adolescents 13 to 17 years of age living in
New York City (NYC). In this analysis, we sought to estimate the effect of VFC eligibility on
vaccine series completeness independently from a number of important individual-level variables
that are of significance in the literature.

2.2 Methods
2.2.1 Data

In this study, we analyzed secondary demographic and vaccination data obtained from the NYC
Citywide Immunization Registry (CIR). Since its inception in 1997, the CIR has been a central
repository for all children’s birth and vaccination records in NYC. As of the time the study data
were retrieved (December 2015), the CIR contained over 6 million individual records and over
76 million immunization events, and had a high level of data reporting, completeness, and
timeliness. By law, all providers who immunize children under the age of 19 in NYC must
report the information to the CIR. As of December 2015, over 90% of NYC providers reported to
the CIR on a regular basis and over 92% of all immunizations administered in the City were
reported within 30 days of administration (CIR 2015 Annual Report), making it an ideal data
source for this type of study. From the CIR database, we identified all children who were 19 to
35 months old as of December 31, 2015 with dates of birth ranging from January 1, 2013 to May
31, 2014. Similarly, all adolescents 13 to 17 years of age born between January 1, 1998 and
December 31, 2002 were identified. Eligible children and adolescents were those who reside in
NYC (based on the most recent address) and have at least 2 childhood immunizations (children)
or 1 adolescent immunization (adolescents) in the CIR. A childhood immunization was defined
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as any vaccine in the primary series: DTP (diphtheria/tetanus/pertussis), polio, MMR (measles,
mumps, rubella), Hib, HepB, varicella, and pneumococcal. An adolescent immunization was any
vaccine from the following series administered from age 9 through 17 years: DTP, HepA, HepB,
HPV, influenza, meningococcal, MMR, pneumococcal, polio, and varicella. The eligibility
criteria follow guidelines used by the CDC’s Immunization Information Systems Support Branch
(IISSB) for its annual assessment of immunization programs across the US61. For the children’s
group, we excluded from the dataset records that contained only 2 immunizations administered
within the first month of birth. The assumption is that these records are reports of the first HepB
vaccine recommended at birth and a duplicate report of the same shot since no other vaccine is
recommended within 30 days of birth.

The choice of the 19 to 35 months and 13 to 17 years age groups was guided by a number of
factors. First, vaccination coverage differences among children can best be appreciated among
those under the age of 36 months. Because the majority of the ACIP-recommended vaccines are
also required for school attendance, many studies including the National Immunization Survey
(NIS) that compare rates of coverage among children use data on preschool children younger
than 36 months. Second, the cohort of choice for the NIS yearly childhood survey is the 19-35
month-old group and the 13-17 year-old group for the teen survey. Therefore, many studies use
these two age cohorts for ease of comparison to the NIS.

Sample selection and deduplication

The 2015 American Community Survey (census bureau) estimates the 19-35 month-old
population living in New York City at 155,000 and the number of adolescents aged 13 to 17
years at 497,63062. A higher number of records was found in the CIR for these children since the
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database contains duplicate records and also records of children who may have migrated out of
the city but are still active. Out of the universe of 19-35 month olds identified in the CIR, a
simple random sample of 24,000 records was drawn for this analysis and cleaned using the
registry’s deduplication process. The Simple Random Sampling (SRS) method was used for both
cohorts. The size of each sample was chosen to provide acceptable level of power to the analysis
while minimizing manual merging.

To merge potential duplicate records, the CIR uses an Artificial Intelligence (AI) matching
software designed to replicate the human decision-making process. The software, which utilizes
a probabilistic approach to matching, includes a series of complex rules and clues or features, the
combined weight of which produces a matching probability, such that the higher the probability,
the more likely 2 records belong to the same patient17. The CIR’s matching software makes a
definite decision on 96.2% of records evaluated and has 98.6% accuracy63. The program can be
used as a stand-alone option to deduplicate files of various sizes. We used the stand-alone
matching program to identify duplicates for the sample records analyzed in this study. All
duplicate records identified for by the program were merged manually and the resulting files
only contained records matching uniquely to the children and adolescents selected for the
analysis. After exclusion of ineligible records, a total of 21,881 children remained in the final
sample. Similarly, 24,000 adolescents were randomly selected initially which yielded a final
sample of 22,420 records.

2.2.2 Study variables
The exposure of interest was eligibility to the VFC program, defined as having received any of
the childhood or adolescent series vaccines through VFC. In the CIR, the funding source of each
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immunization is captured and VFC is one of the categories. In our data, VFC eligibility was
coded dichotomously. The primary outcome of the study was vaccine series completeness or upto-date status. This was defined as the receipt of all age-appropriate immunizations
recommended by the ACIP. For children the schedule recommends the 4:3:1:3:3:1:4 series (4
DTP, 3 polio, 1 MMR, 3 Hib, 3 HepB, 1 varicella, 4 pneumococcal), and the 1:1:3 series (1 Tdap,
1 meningococcal, 3 HPV) for adolescents. Every record in the CIR is evaluated by a program
called the Immunization Calculation Engine or ICE that determines whether or not a vaccine is
valid and whether a child is up-to-date with all ACIP-recommended immunizations based on the
child’s age at the time of the review. The result of the up-to-date evaluation is captured in a
database field in the CIR. Vaccine series completeness status was measured at the time of data
retrieval (cut-off date of December 31, 2015). In addition, we included a number of individuallevel socio-demographic covariables in the analysis based on the findings of prior research. The
variables that were available in the CIR and included in the analytic datasets were: child’s age,
gender, race, ethnicity, mother’s age (at child’s birth) and nativity status, facility funding type
(private/public) and facility type (VFC-enrolled versus not enrolled). Child’s age, measured in
months for the younger cohort and years for the adolescents, was used as a continuous variable.
Mother’s nativity status was derived from the mother’s country of birth reported on the birth
record and dichotomized into US-born and foreign-born. Mother’s nativity was available only
for the 19-35 month-old group; the field was only recently added to the Vital Statistics
submissions to the CIR. The covariates were considered in the analysis for their theoretical
significance. They may be responsible for differential uptake in our samples though they are not
likely to be on the VFC-vaccine series completeness pathway. In addition to presenting the
results by VFC status, our main exposure of interest, we present the findings for the relationship
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between individual-level socio-demographic characteristics and immunization completion status,
as our adjusted models included all of the relevant available characteristics.

2.2.3 Statistical analysis
Descriptive statistics (frequencies and proportions for the categorical variables and means for the
continuous variables) were applied to assess the demographic and vaccination profiles of the
groups. We also performed statistical tests between vaccines series completeness and VFC status
controlling for the covariables that may include potential confounders, using multivariate
regression models in SAS v9.4. Furthermore, to be able to draw conclusions on the impact of
HPV vaccination on overall completeness among adolescents, we also used completeness of
HPV series and the combination of the Tdap, meningococcal and HPV initiation as outcomes of
interest in separate models. Due to the cross-sectional nature of our data, we estimated
prevalence ratios for vaccine series completeness, a choice that is supported in many recent
works that demonstrate the fitness of this measure for these types of data64, 65. The prevalence
ratio is also preferred when the outcome is not rare since in this instance, the odds ratio will tend
to overestimate the risk ratio66,67. In our data, 67.8% of the children and 25.2% of the adolescents
had completed their vaccine series at the time of the review. In the epidemiological literature, the
preferred statistical method for the estimation of the prevalence ratio is the log binomial
regression, which directly models the prevalence ratio, or the Poisson regression with robust
variance when data fail to converge with the log binomial method64, 68, 69. The log binomial and
Poisson methods are both generalized linear models. When prevalence is high as is the case in
these data, the robust Poisson will have less bias than the log-binomial method and will produce
robust standard errors for the regression coefficients64. The log binomial models explored in this
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analysis proved less than optimal and did not converge in some cases. Therefore, we present the
results of the robust Poisson models.

2.2.4 Sensitivity analysis
We conducted a sensitivity analysis to determine whether type of facility introduced bias in the
data. VFC and non-VFC facilities may differ in some of their characteristics, in particular the
reporting of immunizations. Although all providers are mandated to report all immunizations by
law, there may be differential reporting whereby providers enrolled in the VFC program report
more frequently and report more complete data since reporting is a prerequisite to maintain
eligibility in the program. Since each observation included last facility information (medical
home), the samples were stratified based on type of facility in a separate sensitivity analysis.

2.2.5 Missing data
Missing data were found for a large number of observations in the adolescent cohort, in
particular for race, ethnicity, and mother’s country of birth. We ran regression models using two
different approaches to handling missing data for race and ethnicity. For one approach, we only
included cases with complete data. For a second approach, we added missing as a category to
the measures. The latter approach did not change the results substantively and we present the
data with missing as its own category. Since few observations contained mother’s country of
birth, mother’s nativity was excluded from the analysis of the adolescent group.

2.3 Results
2.3.1 Children cohort
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A total of 21,881 children aged 19 to 35 months were included in the analysis. Among them,
51% were male and 49% female (Table 2.1), the average age was 27.1 months (±0.03) and the
average number of immunizations received was 19. Sixty-eight percent of the children selected
had completed the primary childhood series and were up-to-date. The average mother’s age at
the birth of the child was 29.5 (± 0.2) years. In this sample, 43% of the children were born to
foreign-born mothers compared to 40% born to US-born; data for this variable were missing for
17% of the cases. In unadjusted analyses, VFC status had a statistically significant relationship
with vaccine series completeness among all facilities (PR=1.20, p<.0001, Table 2.2.1). In the
adjusted model, the factor remained significant but the effect was attenuated (PR=1.06,
p<.0001). When we stratified by type of facility (VFC enrolled/not-enrolled), the adjusted
prevalence ratios for the relationship between VFC status and vaccine series completeness were
lower and not statistically significant. Estimates for selected covariables are shown in Table 2.3.

2.3.2 Adolescent cohort
The adolescent sample contained a total of 22,420 adolescents of whom 51% were male and 49%
were female (Table 2.1). The average age in this group was 15.0 years (±0.03) and the average
number of adolescent immunizations was 7.6. Thirty-seven percent of the adolescents had
initiated the HPV vaccine series with at least one dose, and 26.3% had completed the 3-dose
series. In contrast, 86% and 94% had completed the meningococcal and Tdap series respectively.
Overall, 25.4% of the adolescents were up-to-date with the ACIP 1:1:3 schedule and were
therefore complete. In the unadjusted analysis, VFC-eligible adolescents were 1.90 times as
likely to be up-to-date with the complete vaccination series as non-VFC eligible adolescents
(Table 2.2.2). When adjusted, the relationship remained strong with a prevalence ratio of 1.72
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(p<.0001) (Table 2.3).

When we stratified the data by facility VFC status, we found that the

prevalence ratios for vaccine series completeness were 1.73 and 1.74 among VFC and non-VFC
facilities respectively (Table 2.2.2).

In addition, we computed prevalence ratios for completion of HPV vaccine and the combination
of Tdap, meningococcal and HPV initiation separately. Among all facilities, the prevalence ratio
for the completion of the 3-dose HPV series between VFC and non-VFC eligible adolescents
was 1.68 (p<.0001) and statistically significant (Table 2.4.1). HPV initiation and completion of
the other 2 vaccines in the adolescent series was also higher among VFC-eligible adolescents
(PR=1.59. p<.0001) (Table 2.4.2).

2.3.3 Other individual level factors associated with vaccine series completeness
In both children and adolescent adjusted analyses, we found that Hispanics were more likely to
be up-to-date with vaccinations than non-Hispanics (PR=1.24, p<.0001 and PR=1.23, p<.0001
for children and adolescents respectively, Table 2.3). Results also indicate that females were
more likely to be up-to-date than males among the adolescents (PR=1.26, p<.0001).

2.4 Discussion
This analysis is the first to use the NYC registry data to examine the relationship between VFC
status and vaccine series completeness while controlling for the influence of a wide range of
hypothesized confounders. Our results demonstrate that VFC eligibility did not have a
substantive effect on being up-to-date among children 19-35 months of age. This finding is very
encouraging, as it may be a sign that the disparity in coverage between VFC-eligible and
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privately-insured children reported by several previous studies is waning. Similar findings were
reported recently by a group of researchers using NIS-Flu data for the 2011 through 2013
influenza seasons. The report concluded that coverage for VFC-insured children differed only
slightly from coverage for the privately-insured (2011–2012 season: 52.0% ± 1.9% versus
50.7% ± 1.2%; 2012–2013 season: 56.0% ± 1.6% versus 57.2% ± 1.2%)70. More research is
needed to confirm this encouraging trend. While VFC status does not appear to be a factor on
vaccine series completeness, the impact of VFC status on timeliness of required immunizations
may be an area for future inquiry. In this group, we also found significant disparities by race and
ethnicity where Hispanic children had a higher prevalence of vaccine completeness compared to
their non-Hispanic counterparts, and Asian, and Black children fared better compared to white
children. Future studies may examine the causes of such disparities.

In contrast to the findings in the younger group, this study shows that eligibility to the VFC
program is a strong predictor of overall vaccine series completeness among adolescents, with
VFC eligible adolescents nearly twice as likely to be vaccinated as those not eligible. These
findings must be seen in light of some important considerations. HPV appears to be a significant
driver in the overall adolescent vaccine completion. Although coverage for Tdap and
meningococcal is above 86%, overall adolescent vaccine completion is only 25% because of low
uptake of HPV in this population. Coverage for the 3-dose HPV series is at 26% (37% for
initiation of the vaccine). We compared estimates obtained for the meningococcal vaccine to
those of the HPV vaccine to shed more light on the effect of the VFC program among
adolescents. Similar to the HPV vaccine, meningococcal is not required for school and uptake of
the vaccine should be concordant with uptake of HPV ideally. This comparison demonstrated
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that the effect of VFC status on meningococcal uptake is largely attenuated compared to the
effect on HPV (PR=1.10 vs. 1.52; Table 2.5), indicating a greater effect of VFC status on HPV
uptake. A few hypotheses may explain these results. First, this may be the result of early
provider resistance to stocking and offering the costly vaccine, a behavior that is reported in
several previous studies. Second, many adolescents are able to make independent decisions
regarding vaccination and seek care on their own and many are likely to use safety-net clinics
where it is easier to obtain the vaccine free of charge through the VFC program without parental
intervention. Third, new addresses are reported to the CIR only when a new immunization is
administered by a NYC provider. Hence, it is possible that children or adolescents who no longer
live in the city were included in the samples due to lack of updated addresses. This scenario is
more likely to affect the adolescent group since the age range included in the study is much
larger than that of the children’s group. Also, if migration patterns between VFC and non-VFC
eligible children and adolescents are differential (e.g. more non-VFC individuals move out of
NYC), including those who no longer reside in the city has the potential to bias our estimates
differentially and away from the null. Lastly, although VFC status is associated with higher HPV
vaccine uptake, other barriers exist. The vaccine is a fairly recent addition to the adolescent
schedule that faces barriers of acceptance and lack of public awareness.

Other findings from these analyses are worth noting. In both groups, Hispanics had superior
coverage compared to non-Hispanics. These findings are consistent with those of several recent
studies, in particular a recent 2016 study in which researchers investigated the impact of the VFC
program on race, ethnicity and income disparities in vaccination coverage using NIS data from
1995 to 2013. The report concluded that income disparities have decreased considerably since
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the start of the program, and showed that the largest gains in coverage over the study period were
among Hispanic children71. Another salient finding in our study was that female gender was
significantly associated with vaccine series completeness among adolescents. The prevalence
ratio was 26% (p<.0001) more for females compared to males. HPV was recommended for
females several years before the vaccine was licensed for use in males. It is possible that uptake
among males is still lagging, which would explain why adolescent series completeness (which
includes HPV) is higher among females than males. In fact, in the comparison with
meningococcal vaccine, we found no significant difference based on gender. Ethnicity and
gender were examined as secondary exposures, therefore the estimates discussed above represent
only their direct effects. Further examination of the data could provide more precise estimates of
their total effects on vaccine series completeness.

Our study has multiple strengths. First, data were drawn from a mature, population-based
registry that captures birth records and immunization reports from providers. For this reason, we
are fairly confident that the population captured in the registry, and subsequently in the study
samples, is representative of the NYC population. In addition, the vaccination data used in this
analysis were submitted by the immunizing providers and are therefore considered highly
accurate.

Our study also has some limitations. First, important factors such as family, neighborhood, and
provider characteristics were not included in the analysis. Previous studies have shown that
family characteristics such as size and dysfunction level, and provider recommendations
influence the completion of recommended vaccines, and these variables could also shed more
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light on the role of VFC status. A second limitation was the missing data on race, ethnicity and
nativity among the adolescent group due to the fact that the CIR did not collect this information
consistently. Having such data would have strengthened the conclusions of the study. Future
research would benefit from applying imputation methods for missing race/ethnicity data, for
example using address information and surname as suggested by Grundmeier et al.72 Third, New
York City’s demography is unique in the nation and its population is diverse in many aspects.
While these results reflect the demography of the city, the extent to which the findings are
generalizable to other geographical areas and populations is not known. Lastly, the large samples
used in this analysis may have increased the likelihood that children or adolescents from the
same households were drawn (i.e. households with more than one child had more chances of
being represented). We believe that such occurrence would be rare and not enough to violate the
independence assumption held by the regression method used in the analysis.

2.5 Conclusion
Our findings show no substantive VFC-associated vaccination coverage disparity among young
children but found evidence of disparities among adolescents. For adolescents, having private
insurance may be worse than being on Medicaid or having no insurance at all, as has been seen
in previous studies73,74. The HPV vaccine is a significant driver in the completion of the overall
adolescent series and efforts to improve adolescent coverage should target uptake of HPV. In
addition, this study found that adolescent coverage is lower than that of children, and adolescent
males and non-Hispanics had lower rates of completeness. Evidence-based research that focuses
on the relationship between VFC status and non-economic factors are also essential in this
discussion. For example, the inclusion of neighborhood characteristics may provide a better
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understanding of the degree to which eligibility to program is modified by such factors.
Neighborhood characteristics such as SES, racial/ethnic homogeneity, and provider
concentration can serve to inform public health action in identifying and targeting areas or
clusters of low coverage, and leveling the playing field between adolescents of all socioeconomic and ethnic groups.
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TABLES
Table 2.1
Demographic characteristics of samples of children and adolescents by up-to-date (UTD) vaccination status,
NYC Citywide Immunization Registry data, 2015
19-35 months
N (%)

13-17 years
N(%)

Total

UTD
14828 (67.8)

Non-UTD
7053 (32.2)

UTD
5699 (25.4%)

Non-UTD
16721 (74.6)

VFC status
Eligible
Not Eligible

11319 (76.3)
3509 (23.7)

4621 (65.5)
2432 (34.5)

4803 (84.3)
896 (15.7)

11744 (70.2)
4977 (29.8)

Gender
Female
Male

7351 (49.6)
7477 (50.4)

3459 (49.0)
3594 (51.0)

3103 (54.4)
2596 (45.6)

7854 (47.0)
8867 (53.0)

Race
Asian
Black
White
Other race
Unknown

2282 (15.4)
3288 (22.2)
5919 (39.9)
2251 (15.2)
1088 (7.3)

825 (11.7)
1253 (17.8)
3091 (43.8)
668 (9.5)
1216 (17.2)

436 (7.7)
768 (13.5)
535 (9.4 )
669 (11.7)
3291 (57.7)

738 (4.4)
2499 (14.9)
1915 (11.5)
1324 (7.9)
10245 (61.3)

Ethnicity
Hispanic
Non-Hispanic
Unknown

4803 (32.4)
8799 (59.3)
1226 (8.3)

1207 (17.1)
4487 (63.6)
1359 (19.3)

814 (14.3)
871 (15.3)
4014 (70.4)

1611 (9.6)
2601 (15.6)
12509 (74.8)

Mother’s nativity*
US-born
Foreign-born
Unknown

5800 (39.1)
7088 (47.8)
1940 (13.1)

2929 (41.5)
2442 (34.6)
1682 (23.8)

8 (0.1)
97 (1.7)
5594 (98.2)

13 (0.1)
283 (1.7)
16425 (98.2)

Mother’s age
≤34
35-44
≥45
Unknown

10802 (72.8)
3004 (20.3)
57 (0.4)
965 (6.5)

4535 (64.3)
1256 (17.8%)
29 (0.4%)
1233 (17.5%)

3619 (63.5)
770 (13.5)
15 (0.3)
1295 (22.7)

10696 (64.0)
2171 (13.0)
47 (0.3)
3807 (22.8)

Facility funding type
Private
Public
Unknown

11311 (76.3)
3513 (23.7)
4 (.0)

5570 (79.0)
1473 (20.9)
10 (.1)

4024 (70.6)
1667 (29.3)
8 (.1)

12745 (76.2)
3934 (23.5)
42 (.3)

Facility type
VFC
Non-VFC

14462 (68.9)
366 (40.8)

6522 (31.1)
531 (59.2)

5469 (96.0)
230 (4.0)

15718 (94.0)
1003 (6.0)

*

This field was incomplete in most adolescent records
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Table 2.2.1
Unadjusted and adjusted prevalence ratios for childhood vaccines series completeness by VFC status among
children 19 to 35 months old, NYC Citywide Immunization Registry data, 2015
All Facilities
Unadjusted
Adjusted1
VFC status
Eligibler

1.20 (<.0001)

1.06 (<.0001)

Unadjusted

VFC Facilities
Adjusted1

1.16 (<.0001)

Non-VFC Facilities
Unadjusted
Adjusted1

1.02 (<.13)*

1.03 (<.71)*

.97 (<.80)*

r

Reference category: non- VFC eligible
* Not significant
1
Total VFC effect adjusted for gender, age, race, ethnicity, mother’s age, mother’s nativity status, and facility funding type (private/public).

Table 2.2.2
Unadjusted and adjusted prevalence ratios for adolescent vaccine series completeness by VFC status among
adolescents 13 to 17 years of age, NYC Citywide Immunization Registry data, 2015

VFC status
Eligibler
r

All Facilities
Unadjusted
Adjusted1

VFC Facilities
Unadjusted
Adjusted1

Non-VFC Facilities
Unadjusted
Adjusted1

1.90 (<.0001)

1.93 (<.0001)

1.48(<.001) 1.74 (.0005)

1.72 (<.0001)

1.73 (<.0001)

Reference category: non- VFC eligible
Total VFC effect adjusted for gender, age, race, ethnicity, mother’s age, and facility funding type (public/private).

1
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Table 2.3
Adjusted prevalence ratios for vaccine series completeness by selected covariates NYC Citywide
Immunization Registry data, 2015
19-35 months
Facility Type
VFC Status
Eligible
Non-eligibler

13-17 years

VFC

Non-VFC

All

VFC

Non-VFC

All

1.02 (<.13)

.97 (<.80)*

1.06 (<.0001)

1.73 (<.0001)

1.74 (<.0005)

1.72 (<.0001)

Gender
Female
Maler

1.01 (<16)*

.86 (<.05)

1.00 (<.29)*

1.26 (<.0001)

1.32 (<.03)

1.26 (<.0001)

Age

1.01 (<.0001)

.99(<.24)*

1.01 (<.0001)

1.06 (<.0001)

1.15 (<.004)

1.06 (<.0001)

Race
Asian
Black
Other race
Unknown
Whiter

1.20 (<.0001)
1.14 (<.0001)
1.06 (<.0001)
1.06 (<.15)*

.71 (<.01)
.90 (<.32)*
1.13 (<.35)*
.29(<.0001)

1.17 (<.0001)
1.13 (<.0001)
1.06 (<.0001)
1.06 (<.20)*

1.74 (<.0001)
1.02 (<.67)*
1.34 (<.0001)
1.17 (<.0005)

1.04 (<.89)*
1.07 (<.78)*
.89 (<.75)*
1.04(<.81)*

1.70 (<.0001)
1.01 (<.83)*
1.32 (<.0001)
1.15 (<.001)

1.24 (<.0001)

.82 (<.12)*

1.24 (<.0001)

1.24 (<.0001)

.75 (.41)*

1.23 (<.0001)

.94 (<.24)*

1.31 (<.33)*

.95 (<.32)*

.95 (<.25)*

.63 (.03)

.94 (<.14)*

.93 (<.0001)

.96 (<.30)

.97 (<.01)

Mother’s age

1.00 (<.001)

1.02 (<.001)

1.00 (<.001)

Mother’s
nativity
Foreign-born
US-bornr
Unknown

1.05 (<.0001)

.95 (<.58)*

1.05 (<.0001)

1.02 (<.26)*

1.29 (<.12)*

1.03 (<.19)*

Ethnicity
Hispanic
Non-Hispanicr
Unknown
Facility
Funding type
Private
Publicr

r

Reference category
*Not significant

Table 2.4.1
Adjusted prevalence ratios for HPV vaccine series completeness by VFC status among adolescents 13 to 17
years of age, NYC Citywide Immunization Registry data, 2015

VFC status
Eligibler

All Facilities

VFC Facilities

1.68 (<.0001)

1.70 (<.0001)

Non-VFC Facilities

1.64(<.0014)

r

Reference category: non- VFC eligible
Total VFC effect adjusted for gender, age, race, ethnicity, mother’s age, and facility funding type (public/private).
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Table 2.4.2
Adjusted prevalence ratios for Tdap and meningococcal vaccine completeness and HPV initiation by VFC
status among adolescents 13 to 17 years of age, NYC Citywide Immunization Registry data, 2015

VFC status
Eligibler

All Facilities

VFC Facilities

1.59 (<.0001)

1.61 (<.0001)

Non-VFC Facilities

1.51(<.0001)

r

Reference category: non- VFC eligible
Total VFC effect adjusted for gender, age, race, ethnicity, mother’s age, and facility funding type (public/private).

Table 2.5
Adjusted prevalence ratios for meningococcal and HPV initiation by VFC status among adolescents 13 to 17
years of age, NYC Citywide Immunization Registry data, 2015 - All facilities
Meningococcal

HPV

1.10 (<.0001)

1.52 (<.0001)

Gender
Female
Maler

.99 (<.70)*

1.12 (<.0001)

Age

1.01 (<.0001)

1.03 (<.0001)

Race
Asian
Black
Other race
Unknown
Whiter

1.02 (<.10)
1.03 (<.002)
1.05 (<.0001)
.98 (<.21)

1.32 (<.0001)
1.33 (<.0001)
1.41 (<.0001)
1.18 (<.0001)

1.02 (<.03)

1.17 (<.0001)

.98 (<.03)

.95 (<.004)

Mother’s age

1.00 (<.0001)

.99 (<.22)*

Facility funding type
Private
Public*

1.00 (<.50)*

1.15 (<.0001)

VFC status
Eligibler

Ethnicity
Hispanic
Non-Hispanicr
Unknown

r

Reference category: non- VFC eligible
Not significant
Total VFC effect adjusted for gender, age, race, ethnicity, mother’s age, and facility funding type (public/private).
*
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Chapter Three: A multilevel model to assess effect measure modification by neighborhood
factors on the relationship between VFC status and adolescent vaccine series completeness

3.1 Introduction
Vaccines are one of the most effective preventive public health measures. According to the Child
Health Epidemiology Reference Group, approximately 17% of deaths among children under the
age of 5 worldwide are due to vaccine-preventable diseases (VPDs)75. In the US, the number of
yearly childhood deaths attributed to VPDs is minimal thanks to efforts undertaken at different
levels of government, including the federal initiative that led to the creation of the Vaccines For
Children program (VFC). Implemented in 1994, the VFC program has been a lifeline for
uninsured and underinsured children and adolescents to receive vaccines recommended by the
US Advisory Committee on Immunization Practices (ACIP), putting them on par with those
covered by private insurance plans that provide full coverage for vaccines. The ACIP, which is a
consortium of medical and public health experts responsible for making vaccine
recommendations, currently recommends vaccination against 16 VPDs for children and
adolescents.

ACIP-recommended vaccines are available free of charge through the federal VFC program.
Reports on the success of the VFC program suggest that the program has been very effective in
improving access to vaccination, resulting in significant reductions in morbidity and mortality
nationwide. With the success of the VFC initiative come new challenges. There is evidence from
several reports using nationally-representative data suggesting that vaccination rates are higher
among children eligible for the VFC program, compared to those who never receive VFC
vaccines76,77. In New York City, it is unclear whether such disparities exist. Therefore, we sought
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to investigate whether VFC coverage of vaccines for low-income children and adolescents was
associated with the reverse disparity identified in other populations. To our knowledge, this
study is the first to use NYC data to examine this question.

Previous studies provide some clues to the pathways that influence compliance with vaccination
and coverage differences between distinct groups. In 2010, a multi-level study investigated the
likelihood of human papillomavirus (HPV) vaccination among 1,709 adolescent females (level
1) nested within 274 counties (level 2) from 6 states (level 3)78. The authors reported significant
geographic disparity in HPV coverage: higher state-level poverty was associated with lower
likelihood of vaccination, however higher county-level poverty and lower family income was
associated with higher likelihood of vaccination78. Findings of other studies on multilevel
correlates of vaccination also point to significant independent effects of area-level factors79,80,81.
Recent data from the National Immunization Survey (NIS-Teen 2014) indicate that adolescents
living below the federal poverty level had higher rates of HPV initiation and completion
compared to adolescents of other economic groups82. In addition, significant ethnic disparities in
the receipt of HPV vaccination were also identified with NIS data83,84. In a 2016 publication,
researchers using NIS data for 20,565 female adolescents aged 13 to 17 years concluded that
HPV vaccination was highest among Hispanics, those living in high poverty areas and with
public insurance83. That same year, a study of 1.5 million NYC adolescents 11 to 18 years of
age also reported an association between HPV vaccination and public insurance.85

There are different ways neighborhood-level factors can influence adherence to vaccine
recommendations. One possible pathway is that neighborhood ethnic composition can influence
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acceptance of a vaccine, or vaccination in general, according to the prevailing attitude in the
community86,87. Another possible pathway is that neighborhood socioeconomic level influences
the likelihood of vaccination through the availability of immunizing resources. Typically, low
SES areas are targeted for the implementation of preventive health programs, especially for
children. These programs offer safety-net services that make it easy for eligible children to
receive preventive services, especially immunizations. In the multilevel context, neighborhood
factors may also act as effect measure modifiers. An example of this relationship was
investigated by Gaudino and colleagues who found that the relationship between parental attitude
towards vaccination and the likelihood of vaccination was modified by whether area of residence
provided the convenience of vaccination exemption.88

In this analysis, we examined processes influencing vaccine series completeness among NYC
adolescents using mixed effects models. The relationship of interest is between individual VFC
status and vaccine series completeness; however, we also estimated the independent effects of
neighborhood factors on series completeness and the community-level variation that remains
after controlling for individual-level factors. Furthermore, we examined possible effect measure
modification by concentration of VFC facility within NYC neighborhoods and neighborhood
poverty on this relationship. The hypotheses motivating this investigation are that higher
concentrations of VFC-participating facilities within neighborhoods will increase the effect of
individual VFC status on vaccine series completeness, and that VFC-eligible adolescents living
in high poverty areas will have higher rates of vaccination completion than those living in low
poverty areas.

44

3.2 Methods
3.2.1 Data and sample selection
Individual vaccination data were obtained from the New York City Citywide Immunization
Registry (CIR) for the analysis. The CIR is a registry established in 1997 that currently captures
immunizations administered to individuals under the age of 19. The reporting of immunizations
to the CIR is mandated by law for all providers practicing in the city. In 2015, over 90% of
providers reported data regularly to the CIR and over 90% of immunizations were reported
within 30 days of administration (CIR annual grantee report).

Registry data included

demographic characteristics, vaccination status, vaccination provider, and residential ZIP code.
The residential ZIP code allowed linkage to the American Community Survey (ACS) for
neighborhood-level SES.

The sample included adolescents 13 to 17 years of age who resided in NYC based on the last
address reported to the CIR as of December 2015, for whom a CIR MOGE (Move or Gone
Elsewhere) flag was not present. The choice of this age group is consistent with that used by the
National Immunization Survey (NIS-Teen) and also other recent studies on adolescent
vaccination83,84,89. A random sample of 24,000 records was selected and cleaned through
software and manual deduplication. To the extent possible, duplicated and fragmented records
were merged to ensure that each adolescent was uniquely represented and that each record
represented an accurate immunization history. All sample record and provider addresses were
geocoded using the NYC Department of City Planning GeoSupport program. Records with no
adolescent immunizations (with zero immunization or only childhood immunizations) were
excluded from analysis. The rationale for this exclusion was twofold. First, we wanted to exclude
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children who had never been vaccinated since factors associated with non-vaccination tend to
differ from those associated with undervaccination. Second, records with no adolescent
immunizations may belong to children who have migrated out of NYC. An adolescent
immunization was defined as any valid or invalid vaccine dose administered from age 9 through
17 years (series included: Tdap/Td, HepA, HepB, HPV, influenza, meningococcal, MMR,
pneumococcal, polio, and varicella). The selection criteria and definitions used in the study are
consistent with those used by the CDC for its annual assessment of immunization registries
nationwide (Immunization Information Systems Annual Report guidance)90. One thousand fivehundred and eighty (1,580) records did not satisfy the selection criteria and therefore were
excluded from analysis. A total of 22,420 records were included in the final dataset.

3.2.2 Study variables
Individual-level variables examined were those found significant in the analyses in chapter 2.
They included age, gender, race, ethnicity, a dichotomous variable indicating whether any of the
adolescent vaccines were received through the VFC program, and up-to-date status (UTD) as the
outcome of interest. UTD status was defined as having received the recommended vaccine series
from the adolescent schedule (1:1:3 – 1 Tdap, 1 Meningococcal, 3 HPV), consistent with CDC
guidance for calculating adolescent immunization coverage90.

Neighborhood poverty level and VFC-facility concentration were included to examine their
independent effects as well as potential modifying role in the relationship between VFC status
and up-to-date status. The neighborhood classification followed the United Hospital
Neighborhood (UHF) classification used by the NYC Department of Health and Mental Hygiene
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(DOHMH). UHF neighborhoods are a classification type unique to NYC, which consists of
adjoining ZIP codes sharing similar demographic, economic, and social diversity characteristics.
Neighborhood poverty data were obtained from ACS 2010-2014 data available through the
DOHMH. The variable was classified based on a standardized area-based measure adopted by
the DOHMH for the study of disparities in public health91. The DOHMH standard, adapted from
the National Institutes of Health’s Public Health Disparities Geocoding Project, recommends a 6
or 4 area-based poverty classification. In this analysis, we used the 4-category classification,
<10%, 10 to <20%, 20 to <30%, ≥30%, to represent the percent of individuals with incomes
below 100% of the federal poverty level. VFC-facility concentration for each UHF neighborhood
was derived using unique facilities from the universe of adolescent records in the CIR. A density
score for each UHF neighborhood was calculated as the ratio of the number of VFC-enrolled
providers practicing in an area to the total number of providers in that neighborhood as per the
CIR. The variable was classified into tertiles: low, medium, high neighborhood VFC-facility
density. Neighborhood poverty level and VFC-facility concentration were assigned to each
observation based on the most recent residential address.

3.2.3 Statistical analysis
The data were described using bivariate analyses of the relationship between the individual-level
and neighborhood factors and up-to-date vaccination status as the outcome. In the adjusted
analyses, four multilevel models were explored: an empty model with no predictors (model 1) to
account for the variation in vaccine series completeness (UTD) by neighborhood; a model with
individual-level predictors as fixed effects (model 2); a model including the individual and
neighborhood-level variables (model 3); and model three with the addition of cross-level
47

interaction terms (model 4). Cross-level interaction terms were included in the final model in
order to assess whether the effects of VFC status on vaccine series completeness were modified
by gender, neighborhood poverty and concentration of VFC facilities in the neighborhood of
residence. All analyses were conducted using the SAS GLIMMIX procedure (SAS v9.4, SAS
Institute Inc., Cary, NC) and log binomial models in order to obtain prevalence ratio estimates.

3.2.4 Collinearity analysis
Using neighborhood poverty and VFC-facility concentration as level-2 predictors accounts for
the variability across neighborhoods by poverty and by facility concentration. However, the two
variables may be correlated. Low-income neighborhoods are often targeted for the
implementation of public programs, especially those serving children, thus are likely to have a
high density of VFC facilities. We tested for the presence of collinearity between the two
variables using two different methods. First, we conducted a Spearman rank correlation test
(non-parametric) which resulted in a coefficient indicating the two variables were not highly
correlated (Spearman’s ρ=.20). Second, we tested collinearity using the Variance Inflation
Factor (VIF) which has been used in previous research to detect multicollinearity when variables
are uncentered92,93. We found a VIF of 1.10 (a VIF of less than 10 indicates the absence of
collinearity94,95). Therefore, we included both neighborhood variables in the models.

3.3 Results
Among adolescents in the sample, 49% were female and 51% were male (Table 1). Nearly three
quarters of the sample (74%) had received at least one adolescent immunization through the VFC
program. The majority of providers included in the sample were enrolled in VFC (94%); 74% of
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them were from private medical facilities and 26% from public facilities. Only 25% of the
adolescents had completed the full 1:1:3 combination series. When stratified by vaccine series,
we found that HPV was responsible for the overall low coverage. Only 26% of adolescents had
completed the 3-dose HPV series, from 63% who had initiated the series with at least 1 dose and
53% with at least 2 doses. In contrast, 86% and 94% had completed the 1-dose meningococcal
and Tdap series respectively (Table 3.1). In bivariate analyses, combination series completion
had a statistically significant association with eligibility to the VFC program (prevalence ratio,
PR=1.90, p<.0001). With the multivariable final model, the prevalence of UTD among
adolescents eligible for VFC was 61% higher than among those not eligible (PR=1.61, p<.003)
(Table 3.2). Adolescents living in high poverty neighborhoods had a 33% lower prevalence of
completing recommended vaccines than adolescents living in low poverty neighborhoods
(PR=0.67, p=.022). The medium and very high poverty neighborhood categories, and
neighborhood VFC-facility density were not statistically significant in our model.

Effect

measure modification by the neighborhood factors was not detected in the results of the final
model (Table 3.2).

3.4 Discussion
The primary aim of this study was to assess whether neighborhood poverty and facility density
played a role in the association between VFC status and vaccine series completeness. However,
evidence to substantiate effect modification by neighborhood poverty and VFC-facility
concentration in this relationship was not found. There are possible reasons for not detecting
independent effects or effect modification by neighborhood VFC facility concentration and
poverty in these data. First, about 85% of NYC providers (public and private) are enrolled in the
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VFC program and sixty percent of the children in the sample lived in neighborhoods where at
least half of the facilities were VFC facilities. In this context, other characteristics such as
proximity to the VFC facilities may be more relevant for up-to-date vaccination status, but were
not captured in the data. Second, we used the UHF neighborhood as the geographic unit for this
study. While this unit may be appropriate for calculation of the neighborhood VFC facility
density, it may not reflect area poverty level accurately given that some NYC neighborhoods are
economically heterogeneous. Census tracts are preferred for measuring area poverty, however
we chose the UHF classification for consistency with VFC facility density. In future analyses, we
can consider the use of finer geographic units, census tracts or Neighborhood Tabulation Areas
(NTAs).

While other neighborhood categories were not statistically significant, we found a significantly
lower prevalence of UTD status among adolescents residing in high poverty neighborhoods,
relative to those living in low poverty. It is not clear what characteristics of the high poverty
neighborhoods set them apart from the low and very high poverty areas as they relate to the
outcome. This association is in contrast to the findings of previous studies78,80, including a recent
study using CIR data96, thus warranting further investigation.

Other results obtained from this analysis are consistent with those of previous studies. We found
a substantive and statistically significant association between VFC status and adolescent vaccine
series completeness, as previously reported in chapter 2 and by another recent study97.
Evidence of racial and ethnic disparities in the completion of the 1:1:3 combination series found
in these data is consistent with the results of two recent systematic reviews on the correlates for
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HPV uptake in that Hispanics and Asians were more likely to initiate or complete the 3-dose
HPV series than other ethnic and racial groups respectively98,99.

The conclusions of this study are based on a large dataset drawn from a mature, population-based
registry that has a long-standing reporting mandate. The NYC registry is one of six sentinel sites
selected by the CDC’s National Center for Immunization and Respiratory Diseases (NCIRD) for
maintaining high standards of data quality, completion, and timeliness. Sentinel site data are used
by the NCIRD to monitor vaccination trends and vaccine uptake nationwide, and to conduct
vaccination studies to inform national policy. Despite this strength, the findings of this study are
subject to limitations. The data reflect vaccination policies and a vaccine financing structure that
may or may not apply to other jurisdictions. Vaccine financing systems are not uniform across
states. In several jurisdictions in US, underinsured children can only receive VFC vaccines in
Federally-Qualified Health Centers (FQHC) and Rural Health Clinics (RHCs), a stipulation that
differs from the requirements for VFC-covered children who can receive vaccines in any setting,
private or public, as long as the provider participates in VFC100,101. For the underinsured, the
referral away from the medical home is a barrier to timely vaccination, especially since
privately-insured parents do not typically seek care in public settings. In NYC however, VFCenrolled private providers can vaccinate underinsured children under the age of 19, with no
disruption in preventive care in the medical home102. New York State had been among a handful
of jurisdictions with this policy, before the Affordable Care Act (immunization provisions),
which requires insurance plans to cover all vaccines recommended by ACIP at no cost
sharing103. While about 57% of US children under the age of 19 are eligible to receive all ACIPrecommended vaccines through the VFC program104,105, over 65% of children meet VFC
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eligibility criteria in New York City102. An additional 7% of children who are enrolled in the
State Children’s Health Insurance Program (SCHIP) also receive vaccines through NYC’s VFC
distribution channel102. Access to ACIP vaccines is widespread as a result of the City’s expanded
coverage.

Data used for this study reflect vaccination histories and residential information as reported to
the CIR. Providers have an option to indicate when a patient has moved out of the City but these
reports are infrequent. As a result, many records of adolescents who have moved out of NYC
have incomplete vaccination histories, remain active in the CIR and are included in routine
analyses. Assuming that out-migration patterns between the VFC-eligible and non-eligible
populations are different (e.g. out-migration rates are highest among high-SES, non-VFC
adolescents), this bias can have a differential effect on the study estimates. The relationship
between VFC status and vaccine series completeness may be overestimated as a result of this
bias. Lastly, despite our efforts to deduplicate the records in the sample, it is possible that some
records did not reflect an accurate immunization history due to fragmentation or duplication in
the CIR. Duplicate records are created when the matching software fails to identify and merge
records belonging to the same patient, preventing the correct assessment of immunization status.
In our study, some adolescents may have received all required immunizations but were listed as
not-up-to-date because the sample record was not complete. Incomplete records may also be due
to incomplete reporting. It is believed that VFC providers report more complete and timely data
to the registry than non-VFC providers. However, given the size of the sample and the fact that
nearly 95% of the children were last seen by a VFC-enrolled provider, the difference in reporting
behavior would have biased the estimates only minimally.
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3.5 Conclusion
In conclusion, this study demonstrated that adolescent vaccine series completeness rates were
highest among adolescents eligible for the VFC program and that neighborhood SES and VFC
facility density did not play a significant role in the relationship. Because uptake of the HPV
vaccine is shown to be a significant predictor of overall coverage, studies aiming to improve
adolescent vaccine coverage may focus solely on the barriers to HPV vaccination.
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TABLES

Table 3.1
Demographic and vaccination profile of sample of adolescents aged 13-17 years from the NYC CIR - 2015
Up-to-date with vaccination
N (%)
Total
VFC Status
Eligible
Not eligible

Not up-to-date
N (%)

All
N (%)

5699 (25.4)

16721 (74.6)

22420 (100.0)

4803 (84.3)
896 (15.7)

11744 (70.2)
4977 (29.8)

16547 (73.8)
5873 (26.2)

Gender
Female
Male

3103 (54.4)
2596 (45.6)

7854 (47.0)
8867 (53.0)

10957 (48.9)
11463 (51.1)

Race
Asian
Black
White
Other race
Unknown

436 (7.7)
768 (13.5)
535 (9.4)
669 (11.7)
3291 (57.7)

738 (4.4)
2499 (14.9)
1915 (11.5)
1324 (7.9)
10245 (61.3)

1174 (5.2)
3267 (14.6)
2450 (10.9)
1993 (8.9)
13536 (60.4)

Ethnicity
Hispanic
Non-Hispanic
Unknown

814 (14.3)
871 (15.3)
4014 (70.4)

1611 (9.6)
2601 (15.6)
12509 (74.8)

2425 (10.8)
3472 (15.5)
16523 (73.7)

Mother’s age
≤35
35-44
≥45
Unknown

3619 (63.5)
770 (13.5)
15 (0.3)
1295 (22.7)

10696 (64.0)
2171 (13.0)
47 (0.3)
3807 (22.8)

14315 (63.8)
2941 (13.1)
62 (0.3)
5102 (22.8)

Facility VFC status
Enrolled
Not enrolled

5469 (96.0)
230 (4.0)

15718 (94.0)
1003 (6.0)

21187 (94.5)
1233 (5.5)

Facility funding type
Private
Public
Unknown

4024 (70.6)
1667 (29.3)
8 (0.1)

12745 (76.2)
3934 (23.5)
42 (0.3)

16769 (74.8)
5601 (25.0)
50 (0.3)

-

187 (1.1)
6104 (36.5)
8421 (50.4)
13520 (80.9)
15470 (92.5)

5886 (26.3)
11803 (52.6)
14120 (63.9)
19219 (85.7)
21169 (94.4)

Individual vaccine series
UTD
HPV
UTD (3 doses)
= > 2 doses
= > 1 dose (initiation)
Mening
Tdap
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Table 3.2. Prevalence ratios for mixed models of adolescent vaccine series completeness, NYC CIR data - 2015
Model 1
(Unconditional model)

UHF neighborhood
(probability of UTD
for
a
typical
neighborhood)
VFC eligibility
Eligible
Not eligibler
Gender
Female
Maler
Age
Race
Asian
Black
Other
Unknown
Whiter
Ethnicity
Hispanic
Non-Hispanicr
Unknown
Neighborhood poverty
(% BPL)
<10% r
10 to <20%,
20 to <30%,
≥30%
Neighborhood VFCfacility density
Low
Medium
Highr
VFC
eligible
*
Neighborhood SES
<10% r
10 to <20%
20 to < 30
≥30%
VFC
eligible
*
Neighborhood VFC
Facility density
Low
Medium
Highr
VFC eligible * gender
Female
Maler
Model fit
AIC

Model 2
(level-1 covariates
only)

Model 3
(level 1 and 2
covariates)

Model 4f
(all covariates and
interaction terms)

0.24 (0.0001)

1.84 (<.0001)
-

1.84 (<.0001)
-

1.61 (0.0035)
-

1.24 (<.0001)
1.05 (<.0001)

1.24 (<.0001)
1.05 (<.0001)

1.50 (<.0001)
1.05 (<.0001)

1.47 (<.0001)
1.01 (0.823)*
1.24 (<.0001)
1.06 (0.171)*
-

1.45 (<.0001)
1.01 (0.821)*
1.24 (<.0001)
1.06 (0.168)*
-

1.45 (.0001)
1.02 (0.738)*
1.25 (<.0001)
1.06 (0.144)*
-

1.13 (0.003)
0.93 (0.041)

1.13 (0.003)
0.93 (0.041)

1.13 (0.005)
0.92 (0.031)

0.91 (0.47)*
0.77 (0.07)*
0.96 (0.83)*

0.84 (0.261)*
0.67 (0.022)
0.83 (0.348)*

0.96 (0.76)*
0.96 0.73)*
-

1.04 (0.816)*
0.85 (0.277)*
-

1.21 (0.138)*
1.30 (0.075)*
1.31 (0.103)*

0.86 (0.315)*
1.14 (0.227)*
-

0.79 (.0007)
25031.63

24364.89

24368.98

24298.95

f

Final model
r Reference category
*Not statistically significant

55

Chapter Four: A spatial analysis to identify and describe clusters of low vaccine series
completeness and their association with neighborhood poverty level in New York City

4.1 Introduction

Spatial methods can be used to describe geographic patterns of disease and at-risk populations.
In vaccination coverage analyses, such methods are essential in the identification of local
variations in coverage rates and pockets of need, where herd immunity may be at risk. A number
of spatial analyses of vaccination data exist in the current literature. In 2010, researchers
investigated clustering of nonmedical exemptions and pertussis disease in California among all
children entering kindergarten from five consecutive years of data106. They found that census
tracts within exemption clusters were 2.5 times as likely to be in a pertussis cluster, as those not
in a vaccination exemption cluster106. In a similar investigation, researchers conducted a largescale analysis among 154,000 children under 36 months of age in California to investigate
geographic clusters of underimmunization and vaccine refusal107. Using the same method, they
concluded that underimmunization and vaccine refusal clustered among the 13 counties analyzed
in the study.

In chapter 3, we presented the results of a multilevel analysis where we examined neighborhood
contextual effects on vaccine series completeness. The current analysis adds to chapter 3 using
an ecological design to examine clustering patterns of vaccine series completeness.

Risk

stratification by geographic cluster provides important information about local area coverage and
at-risk children and adolescent populations in New York City (NYC) that can inform targeted
vaccination campaigns. The objective of the analysis was two-fold. The first objective was to
describe vaccine series completeness among the two age groups by neighborhood, using spatial
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scan statistics to determine the statistical significance of identified low-rate clusters. For this
purpose, we tested the hypothesis that vaccine series completeness rates were lower in some
NYC neighborhoods. The second objective was to identify areas of convergence between
vaccine series completeness and neighborhood poverty. Specifically, we examined whether
vaccination coverage patterns coincided with neighborhood poverty level.

4.2 Methods

4.2.1 Study area and data sources
New York City is the largest and most diverse city in the United States (US)108. With a
population of 8.5 million residents (2015 census estimate) and land area of about 302.6 square
miles3 it is also the country’s most densely populated city. There are 2,168 census tracts
distributed across the City’s five boroughs, including residential and non-residential tracts108.
The city is highly urbanized and is a major hub for economic and cultural exchanges as well as
migration. Such a dynamic setting presents unique public health challenges. Maintaining herd
immunity and surveillance of vaccine preventable diseases (VPDs) are among the challenges
within the purview of the city’s Bureau of Immunization (BOI). To that end, the BOI maintains
the Citywide Immunization Registry (CIR) to track vaccination coverage in the population.
BOI’s vaccination and data collection efforts target New Yorkers of all age groups, however
their primary focus is the population of approximately 1.9 million children 0 through 18 years of
age who currently live in the City109. As a result of these efforts, child and adolescent
participation in the CIR is very high. By the end of 2015, over 90% of children and adolescents
had an immunization record in the CIR (2015 CIR grantee report)110. During the same period,
over 90% of NYC providers had reported immunization information to the CIR110, as mandated
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by NYC and New York State laws. Vaccination data used in this analysis were obtained from the
CIR. We also used 2015 census population and poverty level estimates published by the
American Community Survey and maintained by the Department of Health and Mental Hygiene
(DOHMH). Geographic reference layers were obtained from the NYC Department of City
Planning.

4.2.2 Data
Two analytic datasets were used in this investigation. The datasets included records of all
preschool children 19-35 months of age and adolescents 13 to 17 years of age found in the CIR
with last known residence in NYC (last address reported). The selection of these age groups was
based on prior research, and also on their routine use by the National Immunization Survey
(NIS)111, a survey conducted by the Centers for Disease Control and Prevention (CDC) to assess
vaccination coverage at the state and local levels. Individual-level data obtained from the CIR
included each child’s address and an indicator of their status of being up-to-date (UTD) with
vaccination. We used the DOHMH’s desktop GeoSupport program to geocode addresses of
individuals who were up-to-date. Records with no address information or no geocodable address
were excluded from analysis. Individual-level data on children and adolescents were aggregated
at the census tract level. The aggregated dataset included the following variables: Census Tract
(CT) code, latitude and longitude (CT centroids), CT poverty level (percent of individuals living
below federal poverty level), census tract population counts, number of children or adolescents
who had completed the recommended vaccine series per CIR, and proportion of
children/adolescents up-to-date calculated as the ratio of number of UTD children/adolescents to
the census population counts for each group. In addition, the adolescent dataset included a
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variable representing the number of adolescents with at least one HPV vaccine (HPV initiation).
For the purpose of viewing the geospatial data in the context of known NYC neighborhoods, a
similar dataset was created for each group using the Neighborhood Tabulation Area (NTA) as
geographic unit. That dataset included all the variables described above. Immunization and
address data were retrieved from the CIR as of December 31, 2015.

4.2.3 Study variables
The neighborhood-level variables of interest used in the cluster analysis were the number of
individuals who completed the recommended vaccine series and related population counts.
Vaccine series completeness was based on receipt of all age-appropriate vaccines recommended
by the Advisory Committee on Immunization Practices (ACIP). The childhood vaccine
combination series of 4:3:1:3:3:1:4 includes 4 DTP, 3 HepB, 1 MMR, 3 polio, 3 Hib, 1 varicella,
and 4 pneumococcal vaccines112. The adolescent 1:1:3 combination series includes 1 Tdap, 1
meningococcal, and 3 HPV doses112. Vaccine series completeness status was ascertained by a
computer program used in the CIR for routine analyses which considers valid immunizations
(based on appropriate age and dose intervals)113 and generates an up-to-date status indicator. It
was coded dichotomously in the initial individual-level datasets. The spatial unit of analysis
selected for this study was the census tract. Census tracts are small geographic subdivisions that
tend to be homogenous with respect to population characteristics, socioeconomic status and
living conditions114. Census tracts typically have between 2,500 and 8,000 residents114. NYC
Census tracts and NTA codes were obtained from public-access files by the NYC Department of
City Planning. The poverty grouping used in this analysis is a standard grouping used by the
DOHMH in disparity research. It includes 4 categories: 1) <10% below the federal poverty level
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(low poverty); 2) 10 to <20% (medium poverty); 3) 20 to < 30% (high poverty); and 4) 30 to
100% (very high poverty).

This classification draws from recommendations by the National

Institutes of Health’s Public Health Disparities Geocoding Project115,116.

4.2.4 Data analysis
To test the null hypothesis that vaccination coverage is random among NYC neighborhoods, we
modeled the spatial distribution of coverage rates by census tract using Kulldorf’s spatial scan
statistic117 available in the SaTScan software118. This method has been widely applied to
epidemiologic and biosurveillance data119, including previous vaccination studies107,120-123. The
methodology considers all possible spatially contiguous clusters of mapping units124 (i.e. census
tracts), thus minimizing bias from the modifiable areal unit problem. Using this approach, both
the likelihood ratio statistic and relative risk are calculated for every cluster, based on the ratio of
observed to expected counts within each cluster to the ratio everywhere outside of the cluster122.
Under the alternative hypothesis, at least one of the clusters has a risk ratio different from 1
(null) when compared to outside of the circle/cluster on the map124.

In this analysis, the

likelihood ratio statistic was based on the Poisson distribution124 and the associated p-values
were based on 999 Monte Carlo replications. The maximum cluster size was set at 25% of the
population at risk to prevent the formation of very large clusters. Cartographic depictions of the
clusters were created for each dataset with the Google EarthR mapping option available in
SaTScan.

Following identification of the clusters with the spatial scan static, we used the multivariate NTA
datasets to characterize the relationship between neighborhood coverage and neighborhood
poverty using a standard neighborhood classification. The Neighborhood Tabulation (NTA)
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neighborhood classification lent itself to this analysis since the units are fairly granular but easier
to present graphically than census tracts. NTAs are composed of adjoining census tracts and
there are 188 residential NTAs in NYC. Neighborhood poverty categories (described above)
were obtained for the 188 NTAs and matched with the aggregate vaccine coverage data. For each
age group, we used ArcGIS to describe vaccination coverage spatially and in relation to NTA
poverty status.

4.3 Results
4.3.1 Children
After exclusion of non-residential census tracts and census tracts with zero population count, we
analyzed 2,105 census tract areas. The total population of children 19 to 35 months old was
147,936 and the number of children up-to-date was 101,078 (68%) (Table 4.1).

The scan

statistic identified 17 clusters in this age group where the counts of UTD children were lower
than the expected counts. Among the tracts with at least one child up-to-date (non-zero observed
counts), the risk ratio for the clusters ranged from 0.03 to 0.87 (all p-values <0.01) (Table 4.2).
Clusters of low vaccine series completeness are shown in Figure 4.1. They were detected
primarily on Staten Island, Central Brooklyn, and the areas bordering upstate New York (e.g.
Floral Park, Bellerose, and Rosedale).

4.3.2 Adolescents
We analyzed 2,104 census tracts for the adolescent group with a total population of 498,937. In
this group, 114,160 (23%) had completed the 1:1:3 adolescent series and 236,201 (47%) had
initiated the HPV vaccine series with at least one dose (Table 4.1). The spatial scan analysis
detected 24 statistically significant clusters of low 1:1:3 series completeness for this group where
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risk ratio estimates ranged from 0.13 to 0.88 (all p-values <0.02) (Table 4.3). As with the
children’s group, low completion clusters were found largely in Staten Island, and also in areas
bordering the upstate New York counties, the Rockaways, and several Brooklyn neighborhoods
including Sheepshead Bay, Midwood and Flatlands. Higher rates were detected in Chinatown
(Manhattan), Sunset Park (Brooklyn) (Figure 4.2). Twenty-one clusters of low HPV initiation
were also identified with risk ratios ranging from 0.14 to 0.85 (all p-values <0.02) (Table 4.4).
The lowest rates were detected in Southeastern Staten Island (e.g. Charleston, Great Kills, and
Old Town) and a few Southern Brooklyn neighborhoods (Borough Park, Ocean Parkway, and
Madison). Low rates of initiation were clustered in the Staten Island and the border areas (Figure
4.3).

4.3.3 Intersection of neighborhood coverage and neighborhood poverty
Figure 4.4 depicts coverage rates by neighborhood poverty. With the exception of the Bronx,
Staten Island, and the border NTAs, there was no discernible pattern between vaccination
coverage rates and neighborhood poverty. In contrast, high rates (70% and above) overlapped
with most of the high-poverty NTAs in the Bronx. Most of the low-poverty NTAs located in
Staten Island and the border areas overlapped with the lowest coverage rate category. In the
adolescent group, completion rates of 40% and above for the 1:1:3 schedule were sparse. This
was achieved in a handful of locations in Queens, and one NTA in the Bronx and Brooklyn
respectively. The lowest rates (less than 20%) overlapped with low-poverty NTAs in Staten
Island and the Nassau County border NTAs. They were also concentrated in South Brooklyn in
several medium-poverty NTAs (Figure 4.5). HPV initiation rates of 65% and above were
concentrated primarily in the Bronx where poverty was also high. However several medium and
62

low-poverty NTAs in Manhattan and Queens also had high rates (Figure 4.6). Overall, this
analysis showed a trend of suboptimal completion rates in low-poverty neighborhoods, with the
exception of Manhattan Lower West Side (Battery Park, Soho/Tribeca, and the West Village).
Low-poverty NTAs in Staten Island and the border areas had the lowest rates in all three
coverage categories (children completion and adolescent completion and HPV initiation).

4.4 Discussion

The results of our analysis demonstrate that geographic clustering of incomplete vaccine series
occurs in NYC. They also show that low immunization coverage tends to be found in low
poverty neighborhoods. The study findings support the conclusions of a 2013 report on
geographic differences in HPV vaccination in NYC. The author mapped coverage rates by
neighborhood and found low HPV vaccine coverage rates in Staten Island and parts of Brooklyn
including Borough Park and Sheepshead Bay125. Our study also found that overall, higher
vaccination rates tend to cluster in geographic locations that are considered predominantly
Hispanic and Asian. This is consistent with the findings of Papers 2 and 3 on analyses of a subset
of these data.

Furthermore, these findings also concur with those of two recent studies

conducted among NYC sexually-transmitted disease (STD) clinic attendees, where highest HPV
vaccine initiation and completion rates were found among Hispanics and those who lived in
medium and high poverty census tracts, and initiation rates were found to increase with
increasing poverty126,127.

The study identified several low-rate clusters in neighborhoods located at the city border. It is
possible that children who live in border areas are vaccinated outside of the city. For example,
Staten Island children may see providers in neighboring New Jersey, and children in Eastern
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Queens may see Nassau County providers. These providers are not mandated to report to the CIR
since they practice outside of the jurisdiction. Therefore, these children may have incomplete
reports in the CIR.

In this study, 3-dose HPV series completion was 23%; however, the 1-dose initiation was 47%.
The higher initiation rate is an indication that adolescents are catching up with HPV vaccination,
and perhaps a sign that hesitancy toward the vaccine reported in previous studies128,129 is waning.
Among those who initiate the series, there may be specific barriers that impede completion of the
3 doses. This was demonstrated in a recent systematic review of 61 studies on factors influencing
completion of multi-dose schedules in adolescents in which the authors reported that race,
ethnicity, and ease of access to immunizing facilities were associated with HPV series vaccine
completion130. Because these factors can also operate at the community level to drive down rates,
they may be responsible for the coverage rate gap between HPV initiation and completion in our
data.
The study findings are subject to a few limitations. One of the limitations is the use of data that
may contain duplicate immunization records. Since we used the census and all records with
addresses in the CIR for this analysis, it was not feasible to de-duplicate the datasets due to the
large number of records. Children with fragmented vaccination histories who were in fact up-todate may have been classified as not-up-to-date. This bias can result in lower neighborhood
coverage estimates but was considered non-differential among the census tracts.

Another

limitation in this analysis was the lack of updated addresses in the CIR. Addresses are reported to
the CIR when a vaccine is administered. Children with a record in the CIR who have moved out
of the city are considered NYC residents unless the CIR receives indication that they had moved.
A Move or Gone Elsewhere (MOGE) status can be reported by providers but providers rarely
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report that information to the CIR. Lastly, under-reporting by some providers may have
contributed to inaccurate assessment of UTD status or UTD rates in certain neighborhoods. The
strength of the study lies on the fact that the CIR is a population-based registry, therefore all
children born in the City have a record in the registry. In addition to the birth record, vaccination
records are reported to the CIR regularly as per a mandate requiring all providers to report within
14 days of vaccine administration. Also, the data in CIR is of high quality owing to strict
standards providers must adhere to when reporting data to the CIR.

4.5 Conclusion
Our analysis demonstrates significant geographic heterogeneity in vaccination coverage in NYC.
It also identifies trends between neighborhood coverage and poverty supported by previous
reports. The study identifies specific areas of low coverage in NYC, which can help inform
targeted strategies and policies aimed at reducing neighborhood coverage disparities. Future
research should examine the significance of the relationship between vaccine series
completeness and neighborhood poverty found in this study. In addition, researchers may explore
the ecological processes or contextual factors that result in low-coverage clustering. Given
NYC’s population characteristics and settlement patterns, such factors may include
neighborhood socio-demographic homogeneity, housing density, and immunizing facility
density.
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Tables and Figures
Table 4.1 - Census tract population and coverage profile by neighborhood poverty group – Children and Adolescents –
CIR data, 2015.

Age group

Poverty group*

Number
of
census tracts

Average
population (census
tract)

Total
population

Percent UTD
coverage**

Percent HPV
initiation

1
2
3
4

579
671
440
415

54.72
59.03
75.51
104.63

31684
39606
33224
43422
147936

63.07
67.22
72.54
69.92
68.32

-

1
2
3
4

579
670
440
415

168.57
199.54
259.74
369.54

97600
133689
114287
153361
498937

17.55
21.98
25.70
24.94
22.88

34.89
43.77
52.08
54.82
47.34

19-35
months

Total

13-17 years

Total

*Poverty groups: 1= <10% (low poverty); 2= 10 to < 20%; 3= 20 to < 30%; 4= 30 to 100% (very high poverty).
**Childhood schedule UTD: 4 DTP, 3 HepB, 1 MMR, 3 Hib, 3 polio, 1 varicella, 4 pneumococcal. Adolescent schedule UTD: 1 Tdap, 1
meningococcal, 3 HPV.

Table 4.2 Characteristics of statistically significant clusters of low childhood vaccine series coverage detected by SaTScan
analysis - CIR data, 2015.
Cluster
Cluster Centroid
P-value
Risk
Latitude
Longitude
Ratio*
1
40.702648 73.962559
<.0001
0.43
2
40.611488 74.190594
<.0001
0.69
3
40.598084 73.757599
<.0001
0.85
4
40.587910 73.758536
<.0001
0.75
5
40.632191 73.989688
<.0001
0.64
6
40.766417 73.730722
<.0001
0.70
7
40.661519 73.931023
<.0001
0.87
8
40.809706 73.800166
<.0001
0.72
9
40.794426 73.978946
<.0001
0.78
10
40.831854 73.800678
<.0001
0.62
11
40.963292 73.866158
<.0001
0.00**
12
40.882444 73.842648
<.0001
0.82
13
40.653247 74.011068
<.0001
0.03
14
40.822435 73.962330
<.0001
0.21
15
40.860046 73.874226
0.0002
0.04
16
40.651641 73.981278
0.001
0.23
17
40.904060 73.898690
0.013
0.87
*Risk ratio of childhood vaccine series completeness
**Zero UTD children in CTs (observed count was 0)
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Table 4.3 Characteristics of statistically significant clusters of low adolescent vaccine series coverage detected by SaTScan
analysis - CIR data, 2015.
Cluster
Cluster Centroid
P-value
Risk Ratio*
Latitude
Longitude
1
40.641994 73.931292
<.0001
0.63
2
40.536020 74.161803
<.0001
0.51
3
40.573250 73.859803
<.0001
0.59
4
40.632191 73.989688
<.0001
0.22
5
40.702648 73.962559
<.0001
0.13
6
40.647172 73.743050
<.0001
0.61
7
40.677552 73.729242
<.0001
0.54
8
40.673503 73.938838
<.0001
0.73
9
40.762202 73.739702
<.0001
0.79
10
40.709791 73.877098
<.0001
0.62
11
40.769601 73.742256
<.0001
0.77
12
40.846540 73.778458
<.0001
0.72
13
40.725273 73.824872
<.0001
0.37
14
40.909666 73.898171
<.0001
0.65
15
40.725996 73.938333
<.0001
0.41
16
40.653247 74.011068
<.0001
0.00**
17
40.755148 73.953004
<.0001
0.41
18
40.618703 74.016262
<.0001
0.48
19
40.822435 73.962330
<.0001
0.33
20
40.724404 73.783393
<.0001
0.39
21
40.873635 73.849235
<.0001
0.80
22
40.705280 73.834979
<.0001
0.59
23
40.708574 73.978994
0.010
0.59
24
40.677091 73.808761
0.021
0.88
*Risk ratio of adolescent vaccine series completeness
**Zero UTD adolescent in CTs (observed count was 0)

Table 4.4 Characteristics of statistically significant clusters of low HPV vaccine series initiation detected by SaTScan
analysis - CIR data, 2015
Cluster
Cluster Centroid
P-value
Risk Ratio*
Latitude
Longitude
1
40.529619 74.145600
<.0001
0.63
2
40.529619 74.145600
<.0001
0.39
3
40.600980 73.975451
<.0001
0.59
4
40.702648 73.962559
<.0001
0.15
5
40586394 73.778712
<.0001
0.74
6
40.655728 73.833707
<.0001
0.84
7
40.756638 73.714222
<.0001
0.71
8
40.664405 73.933472
<.0001
0.85
9
40.775859 73.751970
<.0001
0.74
10
40.709791 73.877098
<.0001
0.63
11
40.724962 73.818480
<.0001
0.71
12
40.798323 73.816090
<.0001
0.65
13
40.822435 73.962330
<.0001
0.23
14
40.755148 73.953004
<.0001
0.40
15
40.909666 73.898171
<.0001
0.69
16
40.734730 73.948444
<.0001
0.63
17
40.843028 73.812602
<.0001
0.75
18
40.705280 73.834979
<.0001
0.65
19
40.860046 73.874226
<.0001
0.16
20
40.876607 73.826004
<.0001
0.85
21
40.808669 73.961562
.020
0.14
*Risk ratio of adolescent HPV initiation
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Figure 4.1 Low coverage clusters: children 4:3:1:3:3:1:4 series
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Figure 4.2 Low-coverage clusters: adolescent 1:1:3 series
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Figure 4.3 Low coverage clusters: adolescent HPV initiation
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Figure 4.4 Childhood vaccine series completeness by neighborhood poverty – 2015 CIR data

IIT_GIS_ARCSDE.GISIIT.NeighborhoodTabulationAreas_DCP_2014
Percent UTD for 4:3:1:3:3:1:4
< 60%
60 to <70%
70 to 100%

Poverty groups
< 10%
10 to < 20%
20 to < 30%
30 to 100%
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Figure 4.5 Adolescent vaccine series completeness by neighborhood poverty – 2015 CIR data

IIT_GIS_ARCSDE.GISIIT.NeighborhoodTabulationAreas_DCP_2014
Percent UTD for 1:1:3
< 20%
20 to < 40%
=> 40%

Poverty groups
< 10%
10 to < 20%
20 to < 30%
30 to 100%
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Figure 4.6 HPV series initiation by neighborhood poverty – 2015 CIR data

IIT_GIS_ARCSDE.GISIIT.NeighborhoodTabulationAreas_DCP_2014
Percent HPV initiation
< 40%
40 to < 65%
65 to 100%

Poverty groups
< 10%
10 to < 20%
20 to < 30%
30 to 100%
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Chapter Five: Conclusion

5.1 Introduction
Multiple reports in the current literature describe the shortcomings of the US vaccine financing
system, with resulting vaccine series coverage disparities often seen as a reverse disparity.
Vaccines for low-income children are covered by the federal Vaccines For Children (VFC)
program, while children covered by private plans are at a disadvantage since, in some cases, the
plan dictates the level and type of coverage. Substantial variations exist between US jurisdictions
as a result. New York City’s (NYC) vaccination rates on several measures are similar to national
averages, however some of the city’s children and adolescent populations have suboptimal
coverage. The overarching goal of this study was to elucidate the role of the VFC program in
disparities in vaccination status in NYC and to examine whether neighborhood characteristics
contributed to these disparities. With these aims, we conducted three analyses. Below, we
summarize the findings of the analyses, and discuss the study’s strengths, limitations, and
implications for policy and future research.

5.2 Summary of the findings
Using NYC immunization registry data, we analyzed two cohorts of children separately, children
aged 19-35 months and the second was adolescents aged 13 to 17 years.

5.2.1 Children group
There was no substantive evidence of disparities in vaccine series completeness based on VFC
status among children 19 to 35 months of age. Completion of recommended vaccines was only
1.06 times higher among children who received at least one dose from the VFC program
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compared to those who received all their vaccines from private stocks. In addition, coverage rate
differences between children from VFC facilities and those from non-VFC facilities were also
negligible, although some estimates from the analysis of data by non-VFC providers were not
statistically significant. We found coverage disparities based on race and ethnicity where Asian
and Hispanic children had significantly higher rates of completion than children of other races
and non-Hispanic children. Compared to white children, Asians had a 1.17 times higher
completion rate. Hispanic children were 1.24 times more likely to be up-to-date than nonHispanics, after adjusting for VFC status, age, gender, and facility and mother’s characteristics.
Mother’s nativity and age did not have an effect on childhood vaccine series completeness as
prevalence ratios were close to the null.

Contrary to our hypothesis, VFC status had a marginal effect on up-to-date vaccination in
children. A number of reasons may explain this finding which differs from what has been seen
in other US jurisdictions. The first is the city’s approach to vaccine financing that allows
providers to offer VFC vaccines to privately-covered but underinsured children and adolescents,
with no referral away from the medical home. This way, children receive needed vaccines and
missed opportunities are reduced. Second, approximately 85% of all NYC pediatric providers are
enrolled in the VFC program, including most private providers. Such high program participation
results in expanded access of VFC vaccines to children. Third, NYC’s immunization reporting
mandate to the registry creates a climate where providers are well-informed of immunization
requirements and well-connected to the city’s immunization resources. These resources aim to
improve vaccination access and provider coverage rates; they include CIR online access, CIRElectronic Health Record (EHR) interoperability, and vaccination reminder/recall tools such as
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text-messaging. Lastly, the NYC VFC program makes VFC vaccine accountability a priority in
its efforts to encourage vaccination and reporting to the CIR. As a result, public and private
providers enrolled in the VFC program adhere to program standards and are thought to report
well on all children, not just those who are VFC-eligible.

5.2.2 Adolescent group
A different story emerged from analysis of the adolescent group. Male and female adolescents
who received at least one adolescent immunization from the VFC program had 1.72 times the
rate of completing the full recommended adolescent vaccine schedule to those not enrolled in
VFC. Controlling for VFC status and other relevant factors, adolescent vaccine series
completeness rate among females was 1.26 times the rate of males. Similar to the findings in the
children group, disparities based on race and ethnicity were present among male and female
adolescents where Asians and Hispanics had 1.23 and 1.70 times higher coverage, respectively.
In a separate multilevel analysis conducted among adolescents that included neighborhood
poverty and VFC-facility density, the effects of VFC status, gender, race, and ethnicity remained
strong and statistically significant. Neighborhood VFC-facility density had no independent effect
on vaccine series completeness or effect modification on the relationship between VFC and the
outcome. In contrast, we found independent effects of neighborhood poverty on series
completeness where high-poverty neighborhoods showed slightly lower coverage compared to
low-poverty neighborhoods, while no differences were seen with medium and very high poverty
neighborhood categories. This may be due to random variation given no clear evidence of a dose
response.
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We ran a separate analysis to compare the effect of VFC status on uptake of the meningococcal
vaccine and HPV series initiation. Similar to the HPV vaccine, meningococcal is not required for
school and is often administered with HPV simultaneously, thus is suitable for this comparison.
We found that initiation with at least 1dose of HPV was 1.52 times higher among VFC eligible
adolescents compared to non-VFC adolescents, while receipt of the 1-dose meningococcal
vaccine was only 1.10 times higher among VFC eligible adolescents. The disparity between VFC
and non-VFC eligible adolescents was more pronounced for HPV than the meningococcal
vaccine. Perhaps, an indication that cost remains a barrier to HPV vaccination or that the VFCeligible adolescents are more receptive to the HPV vaccine than their non-VFC eligible
counterparts.

5.2.3 Spatial analysis
Coverage rates were aggregated at the census tract level and analyzed to identify spatial patterns
of coverage using the universe of records found in the CIR. This analysis detected significant
clustering of vaccine series completeness within the city’s five boroughs. After including
neighborhood poverty, coverage overlapped with area poverty in particular in the Bronx (highpoverty, high coverage), and Staten Island and the Nassau County border areas (low-poverty,
low coverage). This finding was consistent for all the coverage measures used in the analysis.
This contrasts with findings of multilevel analysis, where high-poverty neighborhoods were
associated with slightly lower coverage compared to low-poverty neighborhoods. The use of
different geographic units in the analyses, United Hospital Fund neighborhoods (N=42) and
Neighborhood Tabulation Areas (N=188), may be responsible for the discrepancy.

77

5.3 Implications for policy and future research

The gains achieved by the implementation of the VFC program are well documented. As in
NYC, many states have expanded access to VFC vaccines for children covered by private plans,
and the benefits of such a system are demonstrated in the findings of this study. New York State
is among a handful of states that have enacted laws mandating coverage of all ACIPrecommended vaccines and restricting deductibles for vaccines by private insurance plans131.
This model called Enhanced-VFC is adopted by only six states (Georgia, Maryland, Michigan,
Minnesota, Utah and New York)132. There are three other models of financing in use: Universal
Select (7 states), Universal (6 states), and VFC-Only (32 states including DC)132. As of 2013,
thirty-two states were VFC-Only states132. Table 5.1 shows a description of each financing
model and number of states where they are adopted. States that have no provisions for coverage
for the underinsured (VFC-only – 32 states) and those where the underinsured can only receive
VFC vaccines in federally-qualified settings, away from the medical home, have more missed
opportunities and lower vaccination rates than those that have a universal vaccine purchase or
enhanced-VFC systems133. In 2004, an Institute of Medicine (IOM) panel concluded that the
VFC program should be replaced by a different federal system that would mandate the timely
coverage of all ACIP-recommended vaccines by all states and by private plans and subsidize the
costs of vaccine products and administration with reimbursement to the plans134. Also, in a
stakeholder commentary on the 2008 National Vaccine Advisory Committee recommendations
on vaccine financing, the author advocates for a comprehensive, nationally-financed
immunization program, making specific references to systems in the United Kingdom and other
developed countries where the immunization programs are managed and financed at the national
level5. Such a system, he argues, allows all children to receive all vaccines, and offers a social
78

equality that is not found in the current US system135. Such a system was in fact proposed in the
2010 Affordable Care Act (ACA). Under the ACA, health insurance plans must provide
coverage for all vaccines recommended by the ACIP, at no cost sharing, i.e. without copay or
deductible, as long as the vaccine is administered by a plan network provider136. The ACA
immunization provision as stated is presented in Table 5.2137. The provision was an opportunity
to eliminate current barriers and many estimate that the problem of underinsurance for
immunization would be largely solved136. However, several years after the ACA was made law,
many states did not comply with its full implementation. Across the country, ACA
implementation varies significantly among states. As of January 2014, only 7 states had chosen
to implement the ACA fully138. On May 4, 2017, however, the US congress voted to repeal the
ACA. Such a decision is expected to roll-back the expansions provided by the ACA, especially
the gains in coverage of essential services including immunizations139-141. Children from lowincome communities will be disproportionately affected under the proposed cuts since these
communities are more likely to be uninsured. Therefore, future research and policy initiatives
should focus on the implications of the proposed changes and make a case for adoption of a
universal and equitable system of vaccine financing where children of all ages and
socioeconomic status are covered. Our study provides evidence that, at least for individuals
under the age 19, such a system holds promise.

In light of the study findings, targeted policy initiatives should also focus on reducing disparities
in HPV vaccine coverage. In our data, VFC-eligible adolescents were significantly more likely to
initiate the HPV series than those who were privately-insured, compared to other recommended
vaccines. This leads us to conclude that real or perceived economic barriers may be responsible
for the low uptake of the HPV vaccine, or that VFC-eligible populations have a different attitude
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toward the vaccine than the non-eligible populations. Depending on private plan provisions,
there may be real or perceived economic barriers on the parents’ side who may not opt for the
vaccine due to its high cost. At the same time, there are real economic barriers on the side of
providers who may not purchase and store adequate supply to vaccinate children with private
insurance due to the high upfront investment, and due to the fact that adolescents are less likely
to present for routine preventive care142. In a 2011 position paper, the Society for Adolescent
Health and Medicine acknowledged that the reasons adolescent vaccine coverage rates lag
behind those for children were mostly financial142. Among the proposed measures, the group
advocated for the elimination of inequities in vaccine purchase prices and third-party
reimbursement to allow providers to acquire the vaccine without financial risk12. Such a measure
would ensure a more equitable access of the vaccine for adolescents with private insurance.

A secondary yet important finding in the analyses was the effect of race and ethnicity on vaccine
series completeness. We found higher uptake of vaccination among Hispanic and Asian
adolescents. This was true for both children and adolescent series coverage. Future studies may
seek to identify the factors that facilitate adherence to recommended vaccines by the two
populations to inform programs. In addition, they may explore the effects of such neighborhood
characteristics as community acceptance and social capital, and access to immunization services,
as well as the pathways through which they influence overall coverage. Studies may also
consider whether the positive relationship between vaccine series coverage and neighborhood
poverty is statistically significant. An in-depth look at the low-coverage neighborhoods identified
in this study is also warranted in order to address the root causes of the disparities.
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5.4 Strengths and limitations

The findings reported in this paper are not without limitations. The data used in the analysis
while of good quality, may not have been complete as there are duplicate and fragmented records
in the CIR and the size of the datasets did not permit complete deduplication. In addition, the
analysis aimed to infer on the NYC population of children and adolescents but may have
included records of subjects who no longer live in NYC. This can have a differential effect on
the study estimates if migration patterns between VFC and non-VFC-eligible children are
dissimilar. The strengths of the analysis are in the nature and size of the data used. Data were
obtained from a mature, population-based registry and were reported to the registry by
immunization providers by law. For that reason, the data are considered accurate and timely.
Supplemental data from other sources (US Census, American Community Survey, Department
of Health and Mental Hygiene) were also highly reliable.

The conclusions of this study are

generalizable to jurisdictions outside of NYC to the extent they have similar demographics,
vaccination policies and vaccine financing system.

5.5 Overall conclusion

The present study aimed to provide an empirical evidence of the role of the NYC VFC program
on the completion of vaccines recommended for children and adolescents. Among children,
coverage with recommended vaccine series was high in most groups, and the effect of VFC
eligibility was minimal overall. For adolescent vaccine series completeness, the VFC effect was
markedly higher than in the younger group, while controlling for factors with known
independent effects on vaccination. Also, the VFC program did not benefit the adolescent group
uniformly as disparities were found within racial and ethnic sub-groups. Furthermore, coverage
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in this group was low compared to the childhood coverage. As demonstrated in this paper, this is
attributed to low HPV uptake, especially among non-Hispanic adolescents. Efforts to improve
overall adolescent coverage must consider the barriers to HPV vaccination. In this analysis, we
also identified geographic variations in coverage citywide and specific neighborhoods and
pockets of need that warrant public health action. Successful control of vaccine-preventable
diseases depends on the ability to achieve and maintain adequate vaccination coverage across all
groups to preserve herd immunity and assure protection for all.
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TABLES
Table 5.1
States approaches to vaccine financing - 2013
VFC-Only
Enhanced-VFC
Program
description

Number
States (as
2013)

of
of

Private
providers
receive free vaccines
for
VFC
eligible
children only

Private providers receive
free vaccines for VFC
eligible and underinsured
children

32 (including DC)

6 (including New York
State)

Universal Select

Universal

All
children,
regardless
of
insurance
status,
receive all ACIPrecommended
vaccines
free
of
charge, except for a
few vaccines
7

All
children,
regardless
of
insurance
status,
receive all ACIPrecommended
vaccines free charge

6

Tables 5.2
The 2010 Affordable Care Act – Immunization Provision
2010 Affordable Care Act (ACA)
Provision
regarding
immunizations

PHS Act section 2713 and the interim final regulations require non-grandfathered group health
plans and health insurance coverage offered in the individual or group market to provide benefits
for and prohibit the imposition of cost-sharing requirements with respect to the following:
■ Immunizations for routine use in children, adolescents, and adults that have in effect a
recommendation from the Advisory Committee on Immunization Practices (ACIP) of the Centers
for Disease Control and Prevention (CDC) with respect to the individual involved. These
requirements do not apply to grandfathered health plans.
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